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Abstract
This thesis explores different aspects of the effect the organization and the level of
vertical integration of an organization have on the investment decisions the firm takes
and subsequently the effect of such decisions on the performance of the firm. This
thesis uses the biopharmaceutical industry in order to investigate these issues due to
the heterogeneity of organizations and of the levels of integration that can be observed
in this industry.
The first chapter is joint work with David Scharfstein. This chapter compares the
clinical trial strategies and performance of large, established (”mature”) biopharma-
ceutical firms to those of smaller (”early stage”) firms that have not yet successfully
developed a drug. We study a sample of 235 cancer drug candidates that entered
clinical trials during the period 1990-2002 and were sponsored by public firms. Early
stage firms are more likely than mature firms to advance drug candidates from Phase
I to Phase II clinical trials. However, early stage firms have much less promising
clinical results in their Phase II trials and their Phase II drug candidates are also less
likely to advance to Phase III and to receive Food and Drug Administration approval.
This pattern is more pronounced for early stage firms with large cash reserves. The
evidence points to an agency problem between shareholders and managers of single-
product early stage firms who are reluctant to abandon development of their only
viable drug candidates. By contrast, the managers of mature firms with multiple
products in development are more willing to drop unpromising drug candidates. The
findings appear to be consistent with the benefits of internal capital markets identified
by Stein (1997).
The second chapter explores the effect of vertical integration on investment be-
havior in the pharmaceutical industry. We study a detailed, project-level sample of
4057 drug candidates that were sponsored by 40 large pharmaceutical firms during
the period 1984-2001. Of these projects, 447 were conducted through a contractual
alliance with another, smaller company that had discovered the drug candidate. The
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existence of these two types of governance structures allows me to compare integrated
and non-integrated projects within the same firm. Controlling for project and firm
characteristics, we document that pharmaceutical firms are more selective in contin-
uing their integrated projects than in continuing projects governed by contract. We
hypothesize that this difference is caused by the rigidity of the contract that governs
non-integrated projects, making them less flexible in adapting to changes in the firm’s
situation. In line with this hypothesis, we document that although more frequently
continued, non-integrated projects have a lower probability of success.
The third chapter explores the internal capital markets of large pharmaceutical
firms. We compare the behavior of those firms in prioritizing projects inside their
internal capital markets between projects they own and projects they manage in
alliance with other firms. Although both sorts of projects are inside the same internal
capital market, we document that the firm treats them differently. We find evidence
that investment in alliance projects is less sensitive to the firm’s cash flow and to the
existence of other projects in the firm. Moreover, we find evidence that diversified
firms have a tendency to invest more in divisions where they are weak and relatively
less in divisions where they are strong.
Thesis Supervisor: David S. Scharfstein
Title: Edmund Cogswell Converse Professor of Finance and Banking
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Introduction
One of the fundamental questions in corporate finance is how capital is allocated to
investments and to what extent does this capital get allocated to the right projects.
In a perfect world with no frictions as described by Modigliani and Miller (1958),
resources would be allocated to projects so that the marginal product of capital is
equal across every project in the economy. In such a world, a frictionless capital
market would be an ideal conveyer of funds to the appropriate projects. Alas, in
the real world, there are many frictions and distortional forces that do not allow the
market to work in such a perfect way. Examples of such frictions are taxes, transaction
costs, information asymmetry, and agency problems.
The purpose of this essay is to deepen our understanding on how capital is allo-
cated to projects by looking at how another potential distortional force, the organi-
zation, affects the allocation of resources to projects and the subsequent performance
of those projects. This essay analyzes three aspects of organization that impact the
firm’s allocation of resources.
First, Chapter 1 compares mature firms to young firms and asks how these two dif-
ferent organizations allocate their resources, and whether one is more suited than the
other to handle the allocation of resources for R&D projects. Why might we expect
the scope of an organization to affect its investment behavior and performance? The
hypothesis is a variant of Stein (1997) who identifies the conditions under which an
internal capital market that allocates funds across n competing projects is preferable
to an external capital market that funds n single-project firms. In his framework,
the problem with single-project firms is that when they have poor investment op-
portunities they may still invest because their managers will be reluctant to return
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funds to shareholders and lose the private benefits that come from running firms and
projects. This is less of a problem in an internal capital market because managers
have a broader range of projects in which to invest, allowing them to get both private
benefits and better projects.
Second, Chapter 2 analyzes large, mature firms and compares the firm’s decision
in allocation of resources between projects the firm owns and projects the firm does
not own. The costs and benefits of vertical integration have been the focus of much
research since Coase (1937) first raised the issue. Most of this research has been
theoretical in nature. There is a smaller empirical literature – summarized in Whin-
ston (2001) – that tries to test various theories by examining the causes of vertical
integration. For example, researchers have examined whether firms that must make
relationship-specific investments are more likely to integrate (Joskow 1985, Baker and
Hubbard 2003) as suggested by a number of theories. There is, however, even less
empirical research on the effects of vertical integration, i.e. on how integration af-
fects firm behavior and performance. This literature has concentrated on the effect
of vertical integration across firms, comparing integrated and non-integrated firms
(Mullainathan and Scharfstein, 2001; Berger, et al., 2004). This work is an attempt
to understand the effects of integration by performing a comparison of integrated and
non-integrated projects within the same firm. In particular, I examine R&D projects
that are fully integrated within a biopharmaceutical firm to those that are governed
through a contract with another firm.
Finally, Chapter 3 analyzes the effect the level of diversification has on the firm’s
decisions. It explores the internal capital markets of large pharmaceutical firms. We
compare the behavior of those firms in prioritizing projects inside their internal capital
markets between projects they own and projects they manage in alliance with other
firms. Although both sorts of projects are inside the same internal capital market,
we document that the firm treats them differently. We find evidence that investment
in alliance projects is less sensitive to the firm’s cash flow and to the existence of
other projects in the firm. Moreover, we find evidence that diversified firms have a
tendency to invest more in divisions where they are weak and less in divisions where
12
they are strong.
This essay studies these question by examining the drug development behavior
and performance of biopharmaceutical firms. Drug development is an ideal setting
in which to address these question for three reasons. First, there is considerable het-
erogeneity in how biopharmaceutical firms are organized. Some are well-established
firms with many drugs on the market and a large portfolio of drug candidates at var-
ious stages of development. Others are early stage firms with no products yet on the
market and no more than one or two drugs in development. Moreover, even among
large biopharmaceutical firms there exists some level of heterogeneity. Some projects
are owned by the firm, others are owned by another firm and a contractual agreement
(an alliance) exists to govern these projects. Second, there is a wealth of detailed,
publicly available information on the project-level investments of biopharmaceutical
firms, namely the clinical trials required by the U.S. Food and Drug Administration
(FDA) to determine the safety and efficacy of drug candidates. Finally, these invest-
ments have measurable outcomes. Thus, one can compare, at a very fine-grained level,
the investment behavior and performance of firms that differ in their organizational
scope.
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Chapter 1
Organizational Scope and
Investment
1.1 Introduction
How does organizational scope affect investment behavior and performance? We
study this question by examining the drug development behavior and performance
of biopharmaceutical firms. We believe that drug development is an ideal setting
in which to address this question for three reasons. First, there is considerable het-
erogeneity in how biopharmaceutical firms are organized. Some are well-established
firms with many drugs on the market and a large portfolio of drug candidates at
various stages of development. Others are early stage firms with no products yet on
the market and no more than one or two drugs in development. Second, there is
a wealth of detailed, publicly available information on the project-level investments
of biopharmaceutical firms, namely the clinical trials required by the U.S. Food and
Drug Administration (FDA) to determine the safety and efficacy of drug candidates.
Finally, these investments have measurable outcomes. Thus, one can compare, at a
very fine-grained level, the investment behavior and performance of firms that differ
in their organizational scope.
Why might we expect the scope of an organization to affect its investment behav-
ior and performance? Our hypothesis is a variant of Stein (1997) who identifies the
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conditions under which an internal capital market that allocates funds across n com-
peting projects is preferable to an external capital market that funds n single-project
firms. In his framework, the problem with single-project firms is that when they have
poor investment opportunities they may still invest because their managers will be
reluctant to return funds to shareholders and lose the private benefits that come from
running firms and projects. This is less of a problem in an internal capital market
because managers have a broader range of projects in which to invest, allowing them
to get both private benefits and better projects.
This basic logic fits closely with the biopharmaceutical industry. The biggest
investments in this industry are the clinical trials that are required for a drug to be
approved by the Food and Drug Administration (FDA)1. A particular drug candidate
must go through three phases of clinical trials on human subjects: small Phase I trials
designed in most cases to test a drug’s safety; larger Phase II trials to test both its
safety and efficacy; and finally very large Phase III trials with as many as a several
thousand subjects. At each point along the way, a company must decide based on
scientific, clinical, and financial information whether to continue to the next, more
expensive phase of clinical trials.
We argue that the managers of early-stage biopharmaceutical firms — those with
only one or two drugs in development — are excessively reluctant to end clinical trials
after Phase I. Pulling the plug then would mean either that the firm would have to
be liquidated or that research on a new drug would have to be started. If the firm is
liquidated, the managers would lose the private benefits that come from running the
company. These private benefits are best thought of as firm-specific human capital.
If the firm is not liquidated, but instead a new research program is begun to replace
the failed one, the managers might also lose private benefits to the extent that their
human capital is tied to the abandoned research program. Therefore, we argue that
managers of early-stage firms would be willing to take marginally uneconomic projects
forward from Phase I to Phase II.
1The most recent estimate of the cost of getting a single drug approved is $802 million (deflated
to 2000). This estimate factors in the expected costs associated with failed attempts to develop a
drug.
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This sort of problem is less severe in mature biopharmaceutical firms with nu-
merous drug candidates in pre-clinical and clinical testing. The managers who make
the decision to move a Phase I trial into Phase II choose among a portfolio of drug
candidates. While they may benefit from moving drugs along in the pipeline, it is un-
likely that they benefit disproportionately from any particular drug being advanced.
Instead, we would expect them to choose to advance drugs with the highest value to
the company, even if the lower-level R&D teams managing specific Phase I trials de-
rive private benefits from continuing their trials. This is the essence of Stein’s (1997)
argument on the value of internal capital markets.
This perspective suggests that: (1) early-stage firms will be more aggressive in
taking trials from Phase I to Phase II; (2) early-stage firms will be more likely to
have unpromising clinical results at Phase II; and (3) early stage firms are less likely
to take a trial forward from Phase II to Phase III.
Financial constraints could mitigate the tendency of early stage firms to be overly
aggressive in moving forward to Phase II. To the extent that firms lack the cash
reserves to fund Phase II trials, we would expect them to be less prone to move
forward and, conditional on moving forward, to have better clinical results. These
low cash firms early-stage firms would therefore also be more likely to move forward
from Phase II trials to Phase III2.
Our empirical results are in line with these predictions. The sample we analyze
consists of 235 Phase I trials for drugs to treat cancer. We find that early-stage firms
are more prone than mature firms to advance into Phase II trials within two years
of initiating their Phase I trial (61.4% vs. 45.3%). Moreover, if an early stage firm
advances to Phase II, the clinical results of the Phase II trial are worse. In Phase
II trials conducted by early stage firms, the percentage of patients exhibiting some
shrinkage of their tumors — a key marker of success of a Phase II trial — is less
than half that of trials conducted by mature firms (6% vs. 12%). Given the poor
2Given the high costs of running Phase III trials — the average cost is estimated by DiMasi et.
al. (2003) at $86.3 million (deflated to 2000) — we would expect few firms to be able to advance
demonstrably unworthy trials from Phase II to Phase III. Instead, we suspect that they would
conduct more Phase II trials.
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performance of Phase II trials sponsored by early stage firms, it is not surprising that
these firms are also much less likely than mature firms to move into Phase III trials
within a three-year period (13.6% vs. 34.9%). This difference is driven to a very large
extent by early stage firms with large cash reserves. These firms bring 75.6% of their
Phase I trials into Phase II, and have an even lower tumor response rate in Phase II
(4% vs. 12% for mature firms). Only 3.2% of these early stage firms proceed to Phase
III (i.e. once in 31 Phase II trials). The cash-poor early stage firms are only slightly
more prone than mature firms to go from Phase I to Phase II, have somewhat worse
clinical results in Phase II trials, and are less likely to proceed to Phase III.
These results point to agency problems in external capital markets that lead to
over-investment. They suggest that internal capital markets play a role in mitigating
these over-investment problems (Stein, 1997) and that large cash reserves exacerbate
the extent of over-investment (Jensen, 1986).
Our findings connect in important ways to three literatures. The first is the
literature on the costs and benefits of internal capital markets. Much of this literature
suggests that internal capital markets lead to investment inefficiencies due to cross-
subsidization of divisions in low-growth industries by those in high growth industries
(Scharfstein and Stein, 2000, Scharfstein, 1998, Shin and Stulz, 1998 and Rajan,
Servaes and Zingales, 2000). Another line of the empirical literature argues that
internal capital markets enable firms to redeploy capital from unprofitable sectors to
more profitable ones (Khanna and Tice, 2001, and Maksimovic and Phillips 2002).
This paper is also related to the literature on free cash flow and investment
(Jensen, 1986) claiming that firms with large cash flows, cash reserves, or debt capac-
ity, tend to over-invest. There are many papers that try to test this hypothesis, but
the ones closest to ours are those that look at investments at the project level. Lang,
Stulz and Walkling (1991) find that the stock price reaction to the announcement
of an acquisition is lower when bidding firms have excess cash flow. More recently,
Bertrand and Mullainathan (2005) find that firms with excess cash flow tend to bid
more for oil and gas leases and that these leases are, on average, less productive.
Finally, our paper is related to the literature on the determinants of success in
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drug development. The closest link is to Danzon, Nicholson, and Pereira (2003) who
estimate the effect of experience on the probability that firms move forward in the
clinical trials process. They find that small firms are slightly more likely than large
firms to advance from Phase I to Phase II, and that the effect is reversed for Phase
II to Phase III transitions. They interpret these findings as evidence that there is
learning-by-doing in the management of clinical trials; however, our findings suggest
that the higher Phase II success rates of large firms may not be the result of learning-
by-doing but rather may be the result of agency problems at small firms that lead
them to bring poor drug candidates into Phase II trials3.
The chapter is organized as follows. The next section outlines a simple framework
to structure our thinking about the agency problems that arise in biopharmaceutical
firms. Section 1.3 outlines the construction of the database and Section 1.4 presents
the results. Section 1.5 concludes.
1.2 A Simple Framework
This section outlines a very simple framework for comparing the investment behavior
of early-stage biopharmaceutical firms to that of mature biopharmaceutical firms. We
model the decision of whether to advance from a Phase I clinical trial, the earliest
and least expensive phase of clinical development, to a Phase II clinical trial. Based
on the results of the Phase I trial, the manager assesses the probability that a Phase
II trial will be ”successful,” and that he would want to go forward to Phase III.
”Successful” is in quotation marks because a clinical trial does not really ”succeed”
or ”fail.” Rather, the results are often difficult to interpret, with reasonable people
differing on the interpretations. For simplicity, however, we suppose that if the trial
is successful, further development of the drug has an expected discounted payoff of
X > 0. If the trial is unsuccessful the expected payoff is zero. Let p2 be the probability
of success. Let I2 be the cost of conducting a Phase II trial. Finally, suppose that
3Cockburn and Henderson (2001) examine the determinants of success at the level of a research
program (e.g. cardiac and circulatory) rather than at the level of a particular drug candidate. They
find that firms
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A is the liquidation value of the compound if it does not advance to Phase II. Then,
the first-best decision rule is to go forward to Phase II provided:
p2X − I2 ≥ A (1.1)
Would an early stage firm use this decision rule? We argue that the answer is
no because the managers (or founders) of early stage firms derive private benefits, b,
from their projects. In this case, the condition would be:
p2X − I2 + b ≥ A (1.2)
As a result, an early stage firm would be more prone to advance to Phase II than
would be implied by the first-best condition 1.1.
What are the managers’ private benefits in the context of drug development? One
possibility is that managers have project-specific human capital that they would lose
if they abandon the project and try to develop another drug. A second possibility is
that managers have firm-specific human capital that they would lose if they abandon
the project and the firm is liquidated. Finally, one can interpret b as a measure of
managerial over-optimism about the expected payoffs from the project.
Like the managers of early stage firms, the managers of drug development projects
in mature firms are also likely to derive private benefits from drug development.
However, unlike early stage firms, the decision of whether to advance to Phase II is
not made by these managers, but rather higher-level managers who choose among
a portfolio of drug candidates. These managers might derive private benefits from
drug development, but there is no reason to believe that they derive benefits from one
particular project over another. Thus, if they cannot choose to undertake all of the
projects, they will choose those with the highest expected value exclusive of private
benefits. This is essentially Stein’s (1997) argument for the efficiency of internal
capital markets.
This simple framework generates two empirical predictions. From a comparison
of 1.1 and 1.2 we get the first prediction.
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Prediction 1 Early stage firms will be more likely to advance from Phase I trials to
Phase II trials
Holding X and I2 fixed, a comparison of 1.1 and 1.2 implies that early stage firms
that go ahead to Phase II, will do so, on average, at lower levels of p2. This generates
a second prediction:
Prediction 2 Early stage firms will be more likely to fail in Phase II clinical trials
There are additional predictions if financial constraints are introduced into the
model. These are most relevant for early stage firms, as mature firms have large cash
flows from existing drugs on the market. If early stage firms do not have the financial
resources to fund a Phase II trial, they will have to finance the trial by raising external
capital. If the project has negative net present value this will be difficult or impossible
to do. If the firm has cash, C, it will have to raise I2 − C, and will only be able to
raise outside capital if p2X − I2 > −C. If C is small, the firm will not be able to
fund projects with significant negative net present value. Thus, we have our third
and fourth predictions.
Prediction 3 Early stage firms with low cash reserves will be less likely to advance
from Phase I to Phase II trials than early stage firms with high cash reserves
Prediction 4 Early stage firms with low cash reserves will be more likely to succeed
in Phase II trials
1.3 Data
In order for a drug to be marketed, the FDA requires that it go through a series of
clinical trials on human subjects. Phase I trials — the earliest and smallest of the
clinical trials — are typically conducted on fewer than 30 patients, are designed to
determine a drug’s safety. For most diseases, these trials are performed using healthy
subjects, although cancer drug trials, the focus of our study, are conducted on subjects
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with the disease. DiMasi et. al. (2003), using a sample of 68 drug candidates in
clinical trials at large pharmaceutical firms between 1983 and 1994, estimate that the
mean (median) out-of-pocket cost of a Phase I trial was $15.2 million ($13.9 million)
deflated to 2000.
Phase II trials are larger and more costly than Phase I trials. They include as
many as a few hundred subjects, use patients with the disease, and are designed to
test both safety and efficacy. The mean (median) cost of a Phase II trial in the DiMasi
et. al. sample was $23.5 million ($17.0 million).
Finally, Phase III trials are typically very large studies, including possibly thou-
sands of subjects. The mean (median) cost of a Phase III trial in the DiMasi sample
was $86.3 million ($62.0 million). After completing these trials, a drug sponsor can
seek regulatory approval from the Food and Drug Administration by filing a New
Drug Application (NDA) 4.
The analysis focuses on clinical trials for the treatment of cancer. There are a
few reasons why we restrict attention to cancer. First, one can only make meaningful
comparisons of clinical outcomes within a disease class. The outcome of a clinical
trial for lung cancer (e.g. tumor response) cannot easily be compared to the outcome
of a clinical trial for hypertension (reduction in blood pressure). Second, in the case
of cancer, there are relatively straightforward, measurable clinical outcomes such as
tumor response. Third, as noted above, Phase I cancer trials include sick patients
so that, in principle, efficacy can be measured at an early stage. We conjectured
that Phase I cancer trials might result in more useful clinical information that could
inform a decision to move to Phase II. (As we will soon see, this did not turn out to
be the case.) Finally, cancer is the disease class with the largest number of clinical
trials during the last decade.
4For certain classes of drugs, a drug’s sponsor will file a Biological License Application, which is
also evaluated by the FDA.
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1.3.1 Sample Construction
The starting point for the construction of our sample is a database we assembled in
conjunction with Thomas Roberts, M.D. The database includes the Phase I clinical
oncology trials described in annual volumes of Papers/Proceedings of the American
Society of Clinical Oncology from 1990-2002. Each year, the American Society of
Clinical Oncology (ASCO) has an annual meeting for its members, mainly medical
clinicians and researchers. Coinciding with the meeting, ASCO publishes (in hard
copy and now on-line) a compilation of abstracts describing research in the field. It is
standard for oncology research groups to submit abstracts describing their research.
These abstracts are not peer-reviewed, and all submitted abstracts are published.
Phase I trials are identified by searching all the abstracts that include in their title
or in the abstract itself the words ”Phase I”, ”Phase I/II”, ”dose-finding”, ”new”, and
”novel”. From this list, only the ones that indeed describe a Phase I clinical trial are
kept. Abstracts that describe one or more of the following are excluded: combination
trials (i.e. trials using multiple drug compounds); agents targeting pediatric cancers;
agents that were previously reviewed by the FDA; radiation therapies or immuno-
therapies; herbal medication; supportive care; and trials on non-human subjects.
Combination therapies are excluded because it is very difficult to determine how
successful a clinical trial is when a compound is tested in conjunction with another
given that it is hard to determine the baseline response rate of the other compound.
It also makes sense to exclude agents targeting pediatric cancers because the approval
process for these drugs is quite different. Agents previously reviewed by the FDA add
to the complexity of the data collection and therefore are excluded. The other trials
are excluded because they are not drugs per se. More details about the sample can
be found in Roberts et. al. (2004).
Table 1.1 provides information on the annual number of abstracts describing Phase
I oncology trials in the database and lists the annual number of abstracts excluded
for each reason. The main reason for exclusion is that the trial is a combination
therapy. There are a total of 2,798 Phase I abstracts identified, but only 1,180 ab-
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stracts describe agents that meet the criteria. These 1,180 abstracts describe 377
drug agents5. There are more abstracts than agents both because there are multiple
abstracts published to describe a single trial, and because there are multiple Phase I
trials on a single drug agent. Not surprisingly, there is a general increase over time
in the number of abstracts and agents meeting the selection criteria.
The identity of the organization sponsoring the trial was collected from two
commercial databases: Thomson’s Investigational Drug Database (IDdb) and PJB
Publications’ PharmaProjects. The sponsors are a combination of public companies
(62.3%), private companies (27.6%), universities and government agencies (10.1%).
58.9% of the Phase I trials are conducted by firms with headquarters in the United
States. Many of the foreign companies in our sample, such as Novartis and Elan
Pharmaceuticals, are listed on U.S. stock exchanges and have significant research op-
erations in the U.S. If the drug is being developed as part of an alliance between two
organizations, we follow PharmaProjects in only counting the sponsor that developed
the agent and is sponsoring the trial. There are several cases in which there are equal
co-sponsors of the trials and we drop these from the sample. We have 175 unique
sponsors in the sample.
Our analysis centers on the 235 Phase I trials undertaken by the public firms in
our database. We exclude the 65 drug candidates sponsored by private firms at this
point because it is difficult to get balance sheet data on these firms, and because these
firms raise issues, such as the role of venture capital, that are beyond the scope of
this paper. We use Thomson Financial’s Thomson Research (formerly Global Access)
to find the tickers of the public companies, their IPO dates and financial details of
the IPO. We merge it with Standard & Poor’s Compustat, Compustat Canada, and
Compustat Global Industrial/Commercial in order to get financial data about the
public companies in our sample. For comparability, all the financial numbers are
converted to U.S. Dollars and then adjusted to U.S. Dollars for the year 2000.
The PharmaProjects database also track compounds through their stages of de-
5There are 351 unique drug agents in the sample, but there are 26 instances where a particular
agent is being developed by two different organizations for different indications.
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velopment, from as early as pre-clinical laboratory studies to FDA approval. Thus,
we were able to reconstruct the timeline of development including follow-on clinical
trials in Phase II and Phase III. We also collected information from this database
on the kinds of cancer the trials were targeting6, the market size of the indication
being targeted, and the pharmacological properties of the drug candidate. The last of
these describes a drug’s mechanism of action in the body, through which it exerts its
therapeutic effect, i.e. it identifies the biological agent or process the drug stimulates
or inhibits. This information will be useful to us in constructing measures of the
novelty of a particular drug candidate.
1.3.2 Information on Clinical Trials
Our study focuses on four aspects of clinical development: the decision of the company
to take the project forward from Phase I to Phase II; the clinical outcome of the Phase
II study; the decision to move from Phase II to Phase III; and ultimate FDA approval.
Table 1.2 provides information on the time between the initiation of the first Phase I
trial and the initiation of the first Phase II trial, as well as the time between Phase
II and Phase III trials. Panel A indicates that the average time between Phase I and
Phase II trials is 25.3 months. Panel B shows that 65% of the Phase 1 trials move
forward within two years and 80% do so within three years (Table 1.3, Panel B)7.
This is about twice as long as the time between initiation of Phase I and Phase II
trials reported in DiMasi et. al. (2003).
The mean time between initiation of the first Phase II trial and first Phase III
trial is 27.1 months (Table 1.2, Panel A), with almost 60% moving forward within
two years and 76% moving forward within three years (Table 1.2, Panel B). The mean
length between trials is comparable to numbers reported in the DiMasi study.
Of course, not all trials move forward to the next phase. As Table 1.2, Panel C
shows, 67% move forward from Phase I to Phase II as compared to 71% in the DiMasi
6Note that Phase I oncology trials do not typically target a specific cancer while Phase II trials
do.
7Based on this distribution, in some of our regression analyzes we will look at the decision to
move to Phase II within two years following the first announcement of Phase I.
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study. Note however that our sample is right censored; for Phase I trials begun later
in the sample, there are only a few years during which the trial could have moved
forward. Given that the lion’s share of Phase I trials move forward within three years,
this right censuring of Phase II trials is not a major issue. Table 1.2, Panel C also
shows that 32% of the trials that make it to Phase II, later move forward to Phase
III. DiMasi’s study finds that 44% of the Phase II trials move forward to Phase III.
Here the right censuring might be more of an issue, because the time between Phase
I and Phase III is four to five years8.
Beginning in Phase II, drug candidates are tested for particular indications, e.g.,
lung cancer, liver cancer, or breast cancer. As Table 1.3, Panel A shows, 54% of the
agents are tested for two or more cancers, with the mean being 2.7 indications. In a
majority of cases (57%), sponsors only have one agent in clinical trials in our sample,
while two sponsors (Bristol Myers Squibb and Novartis) show up sixteen times. The
average is 2.1 agents.
1.3.3 Information on Companies
Table 1.4 presents summary data (deflated to the year 2000) on the public companies
sponsoring the trials in the sample. On average, the public companies are very large,
with mean revenues of over $8 billion, mean assets of almost $11 billion, mean cash
of close to $2 billion and mean R&D of about $1 billion. The average market capi-
talization is over $38 billion and mean Q is 10.2. On average, the firms were public
for almost 26 years before embarking on the Phase I trials in our sample.
These averages mask considerable heterogeneity in the data. The 25th percentile
firm has revenues of only $9.5 million, cash of $41.4 million, R&D of $21.0 million and
a market capitalization of $202.7 million. As we have suggested, there are really two
types of firms that are undertaking clinical trials in oncology. One type is the mature
biopharmaceutical firm with sizable revenues, some (or many) drugs already on the
8As our study will show, the Phase II to Phase III probabilities depend on the type of firm that
is undertaking the trial and the DiMasi study is restricted to mature biopharmaceutical firms. Also,
the transition probabilities and mean time between trials are very similar for public firms and the
rest of the sample.
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market, and a portfolio of drug candidates in clinical trials or in the laboratory. The
other type of firm is an early stage biopharmaceutical, with no drugs on the market
and a limited portfolio of drug candidates (often only one) in clinical trials or in the
laboratory.
Because we do not have direct information on drug revenues by company, our
proxy for whether a firm is early stage is whether the firm has revenues less than
$30 million deflated to 2000. The revenues of these firms typically come from two
sources: milestone payments from other firms as part of alliances and contract R&D
work. There are a few firms with revenues greater than $30 million, but less than
$250 million. We found that these firms all had drugs that were on the market or
about to be on the market, so we consider them mature firms.
Panels B and C of Table 1.4 break out the sample into mature and early stage
firms. Fifty-nine percent of the Phase I trials are done by mature firms, and the
remainder are done by early stage firms. Not surprisingly, the differences between
these firms are very large in terms of cash, R&D, and market capitalization.
1.4 Empirical Analysis
In this section we compare the decisions of early stage and mature firms to move
forward in the clinical trials process.
1.4.1 Basic Analysis
Phase I to Phase II Transition Probabilities
We start by estimating probit models of the decision to go from Phase I to Phase II
within two years. We use a two-year cutoff on the Phase II decision for two reasons.
One reason is that, without a cutoff, Phase I trials that were begun in the early
part of the sample would be more likely to be taken forward. If there is an over-
representation of one type of firm in the early period, this would bias our findings.
The second reason to use a time cutoff is to measure the aggressiveness with which
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firms move forward in the clinical trials process. Note that 69% of the agents that are
taken forward to Phase II by the public companies are taken forward within two years.
To avoid making seemingly arbitrary cutoffs, we will also estimate Cox proportional
hazard models. This allows us to estimate the probability per year that a firm takes
a trial forward.
The key regressor in our model is, Early Stage, a dummy variable for whether
the drug’s sponsor is an early stage biopharmaceutical firm. We also include a set of
controls: information on the clinical outcome at Phase I — response rate and toxicity;
whether the drug is a biologic agent (as opposed to a chemical compound); whether
the drug was sponsored at one point by the National Institutes of Health or any of its
affiliate organizations; the novelty of the agent under investigation; and the potential
market size of the drug.
Before getting to the regressions it is worth simply comparing the Phase II tran-
sition probabilities of the early stage and mature firms. Of the 139 agents sponsored
by mature firms, 63 (45.3%) move from Phase I to Phase II within two years. By
contrast, early stage firms are more prone to advance to Phase II; of the 96 agents
sponsored by early stage firms, 59 (61.4%) move forward to Phase II within two years.
This difference is statistically significant at the 1% confidence level.
The probit regressions in Table 1.5 show that this finding is robust to the inclusion
of various controls. The reported numbers are the marginal effects of a unit increase
in the regressors, not coefficient estimates from the regression. The first column just
replicates the finding discussed above without the controls: the estimated marginal
effect of the Early Stage dummy is 0.161, indicating that early stage firms are 16.1%
more likely than mature firms to move forward to Phase II.
The second column of Table 1.5 adds Phase I clinical data to the regression, but
the Early Stage estimate is unaffected. An increase in the tumor response rate at
Phase I from zero to 10% is predicted to increase the Phase II transition probability
by 9.7%. This estimate is, however, statistically insignificant. This is true of the
other regressors as well. Whether the drug candidate is a biologic agent or a chem-
ical compound has a small, statistically insignificant effect. Prior NIH-sponsorship
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of research on the drug candidate appears to have a large estimated effect on the
probability of moving forward, but here too the estimate is statistically insignificant.
These results are consistent with the view that early stage companies are more
aggressive in bringing drug candidates into Phase II trials because they derive private
benefits from doing so and they, unlike mature firms, do not have a portfolio of other
drug candidates to advance in clinical trials. An alternative explanation, however, is
that early stage are attempting to develop drug candidates that would have higher
payoffs if they succeed (a higher X in our model). In this case, they would use a lower
break-even success probability (p2) in deciding whether to advance to Phase II. For
example, early stage companies might be targeting particular cancers with a large
market size where there are few other approved therapies. It is also possible that the
drug candidates of early stage firms are more scientifically innovative and therefore
would have a higher payoff if they were to succeed.
Column 3 of Table 1.5 reports results that address these possibilities by adding
two controls to the regression. The first control is a set of two market size dummies
that come from estimates in the PharmaProjects database. The first dummy is for
whether the market size is between $500 million and $2 billion, and the second dummy
is for whether the market size is greater than $2 billion. The excluded dummy is for
whether the market size is less than $500 million. Although the estimated effects
of these dummies are positive, they are not statistically significant. Given that an
overwhelming majority of the drug candidates target a market size in the $500 million
to $2 billion range, it is not a surprising finding. In addition, as noted earlier, most
Phase I cancer trials target cancer in general, not specific cancers, so it is unlikely
that there would be much variation in market size at the Phase I stage.
The last regression in Table 1.5 also includes a measure of the drug candidate’s
novelty. Novelty is calculated in the following way. As noted in Section 1.3, PharmaPro-
jects contains a pharmacological description of each drug candidate. Thus, for each
pharmacological description we rank drug candidates chronologically, with the nth
drug candidate chronologically within a certain category getting the rank of n. A drug
candidate with a higher n is considered less novel. For example, in 1989, Schering-
28
Plough was the first to conduct a clinical trial using a DNA antagonist (Tomozolo-
mide). In 2000, Access Pharma also began clinical trials of a DNA antagonist, but it
was the twentieth such clinical trial, making it less novel by our measure. The average
n in our sample of mature firms is 24.6, while the average for early stage firms is 22.0
a statistically insignificant difference.
In the regression in column 3 of Table 1.5, we include the natural log of 1/n as our
measure of novelty. There is a positive, statistically significant relationship between
novelty and the probability of moving from Phase I to Phase II. Nevertheless, there
is no appreciable effect of including the novelty measure on the Early Stage dummy.
This is not surprising in light of the fact that there is little difference in the novelty
of the drug candidates developed by early stage and mature firms.
Performance of Phase II Trials
Prediction 2 suggests that early stage firms will be less successful than mature firms in
Phase II trials. To test this prediction we collected data on the clinical outcomes of the
Phase II trials from abstracts published in Papers/Proceeding the American Society of
Clinical Oncology, the same source we used for information on the Phase I trials. We
record the percentage of patients in a trial that exhibit some tumor shrinkage. This is
a key endpoint used by the industry to measure the success of Phase II oncology trials.
We have clinical data on a total of 201 Phase II trials. These include multiple trials
conducted on a single agent for different indications. We are unable to find clinical
information on a number of the trials that we know were initiated either because
the study was not completed or because the study abstract was never published in
Papers/Proceedings.
Table 1.6 presents summary information on the average tumor response rate re-
ported in the Phase II trials undertaken by the firms in our sample. On average,
the tumors of 9.5% of trial participants showed some response. Consistent with our
prediction, the table also shows that the response rate was nearly twice as high for
the mature firms (12.0%) as for the early stage firms (6.1%). The table also shows
the distribution of clinical trials across twelve different cancer types, with the most
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common being respiratory, digestive, breast, and genital type cancers. There is no
systematic difference between mature and early stage firms in the distribution of tri-
als across these cancer types. The table also shows the percentage of patients in the
trials who received prior treatments for cancer. Again there is no difference between
early stage and mature firms.
Table 1.7 compares the Phase II response rates of early stage and mature firms in
a regression framework. The first column of the table restricts attention to the 108
Phase II trials begun within two years of the initiation of the Phase I trial for which
we also have Phase II clinical data. This column includes no controls and simply
documents that the average response rate in these trials is 4.4% lower for early stage
firms than for mature firms. The difference is not statistically significant. Including
the controls in the regression in the second column amplifies the difference; on average,
early stage firms have a 5.9% lower response rate than mature firms. Evaluated at
the means of the controls, this regression model predicts that the response rate of
patients enrolled in Phase II trials of mature firms will be twice as likely to exhibit
some tumor shrinkage as patients in Phase II trials of early stage firms. The third
column of Table 1.7 shows that the estimated effect is similar if we include all Phase
II trials, not just those begun within two years of Phase I initiation.
Phase II to Phase III Transition Probabilities
Another measure of whether Phase II trials are successful is whether firms proceed to
Phase III trials. Before discussing the regressions, it is useful to compare the mean
transition rates for the two sets of firms. Of the 63 drug candidates brought to Phase
II by mature firms within two years, 22 (34.9%) are later brought to Phase III within
three years. By contrast, only 8 (13.6%) of the 59 drug candidates brought to Phase
II trials within two years by early stage firms are eventually brought to Phase III
trials within three years. This 21.3% differential is highly statistically significant.
Table 1.8 presents the regression analysis. The first column simply replicates the
comparison that we just presented. The other columns add the standard controls,
but none is statistically significant and they do not affect the estimated effect of the
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Early Stage dummy.
Current Status of the Drugs
Yet another measure of success is whether the drug candidate is ultimately approved
by the FDA. In Table 1.10, we present the current status of the drugs. Panel A
shows that 15% of the drugs of mature companies have been approved while only 6%
of the drugs of early stage companies have been approved. In Panel B, we restrict
the comparison to those drugs that had moved to Phase II in 2 years or less. The
differences are amplified for this sub-sample. For the early stage firms, only 8.5%
of the drug candidates were approved by the FDA, whereas for the mature firms,
28.6% were approved. This fact also supports the view that early stage firms are
less selective in the drug candidates they bring forward to Phase II. One caveat to
keep in mind, however, is that given the time is takes to get FDA approval, drugs
that enter our sample relatively late will have a lower probability of getting approved.
This will only explain the difference between early stage and mature firms if mature
firms begin their trials earlier in the sample, but there is no evidence of that.
Sales Revenue
As noted earlier, it is possible that early stage firms are more likely to advance from
Phase I to Phase II not because of agency problems, but because they have more
novel therapeutic approaches and they are targeting larger markets. As we showed,
this is not the case. Moreover, including measures of novelty and market size has no
meaningful effect on the estimates.
Another way to see whether early stage firms are going after higher payoff projects
is to look at their payoffs when they actually succeed in launching a drug. There are
29 product launches in our sample, only seven of which are by early stage firms. We
were able to collect information on product sales in the first three years after the
product launch for all seven launches by early stage firms and 17 of the 22 product
launches by mature firms. The differences are quite striking, but are the opposite of
what one would expect if early stage firms are taking bigger risks. As can be seen from
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Table 1.10, in each of the three years, the mature firms sell considerably more than
the early stage firms. In the first year after launch, the sales of products launched
by early stage firms are $12.7 million on average as compared to $99.7 million for
mature firms. In the second year, the average is $61.3 million for early stage firms as
compared to $141.3 million for mature firms. In the third year, early stage firms sell
$108.4 million, whereas mature firms sell $204.3 million on average.
In five instances, we were unable to find information on the sales of products by
mature firms. One might be concerned that when sales are very low for such firms,
this information is less likely to be disclosed. Even so, if one assumes that sales for
these products are zero, the average sales of products launched by mature firms are
still greater that those of early stage firms in each of the three years following product
launch.
Alliances
Many of the early stage companies in the sample develop their drug candidates as part
of an alliance with a large pharmaceutical company. In these alliances a pharmaceuti-
cal firm typically makes payments to an early stage firm to fund clinical development
in exchange for the right to license and sell the drug if it is approved. In our sample,
62.5% of the drug candidates of early stage companies have some kind of an alliance
at the time of the Phase I trial. One might expect that the alliance limits the ability
of an early stage company to take compounds forward from Phase I to Phase II if they
have little chance of succeeding. This does not appear to be the case in our sample;
there is very little difference in the transition probabilities of drug candidates being
developed in alliances and those being developed solely by an early stage firm. This
finding is consistent with Guedj (2004) who shows that mature pharmaceutical firms
are more likely to advance Phase I clinical trials into Phase II when they are devel-
oping a drug in an alliance with an early stage firm than when they are developing a
drug on their own.
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1.4.2 The Effect of Financial Resources on the Clinical Trials
of Early Stage Firms
The previous sub-section presents evidence that early stage firms are more prone than
mature firms to move forward from Phase I to Phase II, to have worse clinical results
in their Phase II trials (in the form of lower response rates), and to be less likely to
move from Phase II to Phase III. Our model suggests that managers of early-stage
firms are reluctant to pull the plug in early clinical trials even if doing so would be
value maximizing. However, as Prediction 3 indicates, to the extent that the firm
has fewer financial resources, this should put a limit on the ability of management to
over-invest in Phase II trials and should lead to greater success at Phase II (Prediction
4).
To test these predictions, we need a measure of financial resources. We define a
firm with limited financial resources as one with cash of less than $30 million (deflated
to 2000). Our assumption is that all mature firms have ample financial resources
given that biopharmaceutical firms generate very large cash flows (even after their
considerable R&D expenses). Thus, the test really hinges on comparing the Phase I
and Phase II decisions and outcomes of early stage firms based on their cash holdings.
A simple comparison of transition probabilities for early stage firms tells the basic
story. Of the 96 Phase I trials conducted by early stage firms, 55 are conducted
by firms with low cash reserves, and the remaining 41 are conducted by firms with
relatively large cash reserves. Out of the 55 Phase I trials conducted by the low-
cash firms, 28 (50.9%) proceed to Phase II, whereas 31 (75.6%) out of the 41 Phase
I trials conducted by the high-cash firms proceed to Phase II. Thus, the Phase II
transition probability for the low-cash early-stage firms is only slightly higher than
that of mature firms (45.3%), whereas the transition probability of the high-cash firms
is significantly higher than those of the constrained early stage firms and the mature
firms. This result is reflected in the probit regressions in Table 1.11. As before, none
of the controls is statistically significant nor do they impact the estimated effects of
Early Stage dummies.
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Table 1.12 shows that the average response rate of patients in Phase II trials
conducted by high cash early stage firms is particularly low. In the full model with
controls, the response rate of these firms is 9.3% below that of mature firms; the
response rate of early stage low cash firms is 4.7% below that of mature firms. This
basic pattern is robust to including all Phase II trials, not just those begun within two
years of Phase I initiations. The estimated effects for the early stage high-cash firms
are statistically significant. Evaluated at the means of the controls, they predict that
patients enrolled in trials conducted by mature firms will be more than three times
as likely to show some tumor shrinkage as patients enrolled in a study conducted by
high-cash early stage firms.
The findings on the Phase II to Phase III transition are also very striking. Of
the 28 Phase II trials conducted by low-cash firms, 7 (25.0%) went on to Phase III;
however, only 1 (3.2%) out of the 31 Phase II trials conducted by high-cash firms
went to Phase III. The Phase II success rate of the high-cash firms is obviously much
lower than that of the low-cash firms and the mature firms (34.9%). The success
rate of the early stage constrained firms is lower than that of the mature firms, but
the difference is not statistically significant. Again, these finding are reflected in the
probit regressions, which are presented in Table 1.13.
1.4.3 Estimating Proportional Hazard Models
As discussed above, our data is right censored by which we mean that some drugs
may eventually advance to Phase II or Phase III, but we do not yet observe that
event. A Phase I trial begun in 2002 that has not yet transitioned to Phase II is not
the same as a Phase I trial begun in 1994 that has not transitioned to Phase II. We
dealt with this problem by counting as a Phase I to Phase II transition only those
that occurred within two years. Likewise for Phase III transitions, we only counted
those that occurred within three years of initiating Phase II. This approach has the
added benefit of measuring how successful each phase was on the theory that trials
that transition more quickly are probably more highly valued by their sponsors.
Another approach to dealing with right censoring is to use survival analysis. Sur-
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vival analysis examines and models the time it takes for an event to occur. Here we
use the Cox proportional hazard model, following the specification outlined in Cox
(1975). A drug is assumed to have a certain probability of succeeding in each period.
Success is defined as the event of moving from Phase I to Phase II. The instantaneous
probability of success at any given time t is called the hazard rate, h(t), defined as:
h(t) =
Probability of Success between t and ∆t
Probability of Success for times ≥ t (1.3)
The Cox model assumes that the hazard function has the functional form:
h(t) = h0(t)e
β1x1+β2x2+...+βnxn
However, the model assumes no restriction on the function h0(t).
We report the results of our survival analysis in Table 1.14. We use the same
controls as in the previous section. The numbers reported are hazard ratios. In col-
umn 1, the estimated effect of being an early stage company is large and statistically
significant; it indicates that early stage firms have a 58% higher hazard of moving to
Phase II than do mature firms. The second column breaks out high-cash and low-cash
firms. Not surprisingly, the high-cash firms have an even higher hazard ratio; they
are 123% more likely than mature firms to transition from Phase I to Phase II. The
increased hazard for the low-cash firms is 24%, but it is statistically insignificant.
Columns 3 and 4 describe a similar analysis, although in this case we measure the
hazard of moving from Phase II to Phase III. The results on Phase II to Phase III
transitions are similar to those discussed earlier. The hazard ratio for the early stage
firms is 0.39, indicating that their hazard of progressing from Phase II to Phase III
is less than half that of mature firms. This estimate is statistically significant. The
effects for the early stage high-cash firms and early stage low-cash firms are similar.
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1.5 Conclusions
We show that early stage biopharmaceutical firms are more aggressive than mature
biopharmaceutical firms in bringing their drug candidates forward from Phase I to
Phase II clinical trials. However, the drug candidates they bring to Phase II appear
to be less promising; conditional on making it to Phase II, patients in trials conducted
by early stage firms are much less likely to show some tumor shrinkage and these drug
candidates are much less likely to advance to Phase III. These findings are driven to
a great extent by the sub-sample of early stage firms with large cash reserves.
Our findings point to an agency problem between shareholders and managers of
single-product early stage firms who are reluctant to pull the plug on their only viable
drug candidates. We argue that the interests of managers of mature firms are more
aligned with their shareholders. With their large portfolio of drug candidates, man-
agers of these firms are more willing to pull the plug on unpromising drug candidates
because they have other ones they can bring to clinical trials. The findings appear to
be consistent with the benefits of internal capital markets identified by Stein (1997).
There are a number of ways in which we hope to build on this research. First,
it is worth investigating why there are big differences in the behavior of early stage
firms. Part of the answer may lie in understanding why some firms have more cash on
hand than others. One possibility is that firms are more prone to raise equity capital
during periods when biopharmaceutical firms are more highly valued. These funds
give managers considerable freedom in the conduct of clinical trials. By contrast,
when market valuations in this sector are low, firms tend to rely more heavily on
alliances in which control over clinical trials is shared by the firm and its alliance
partner (Lerner, Shane and Tsai, 2003). Thus, understanding the role of the equity
markets and alliances in the clinical trials process is very high on our research agenda9.
Second, we have ignored differences that may exist in the drug development strate-
gies of mature firms. Although our evidence suggests that having more drugs in the
9Guedj (2004) is a first step in understanding the role of alliances in clinical trials. His research
suggests that even with alliances early stage firms are more prone to take drugs forward from Phase
I to Phase II and the fail in Phase II trials.
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pipeline makes firms more selective on average and results in a higher Phase II success
rate, the composition of this pipeline and the organizational structure of these firms
could have an effect on their decision making. For example, if cancer drugs are a
large part of a company’s overall portfolio, is it more or less selective in its decision
to move forward to Phase II? Or if the drug candidate was acquired in a merger, how
does it affect the transition probability?
Finally, it would be worth examining the 65 trials that are conducted by the private
firms in our sample. We suspect that many of these firms are still being funded by
venture capitalists. In theory, it is not clear whether the existence of venture capital
funding exacerbates or mitigates the agency problem in drug development. On the
one hand, venture capitalists fund companies in stages, disbursing funds only when
they are needed. To the extent that venture capitalists are able to assess the prospects
of the drug, they would not choose to fund drugs with low expected payoffs. On the
other hand, the goal of venture capitalists may not be to maximize the value of the
portfolio company, but rather the shorter-run probability that the firm can be taken
public. Gompers (1996) has shown that this incentive is particularly strong among
young venture capital funds with limited track records since they need to convince
potential limited partners that they have made good portfolio investments. Thus,
if a company is better able to go public if it has later stage clinical trials, venture
capitalists may encourage early stage firms to move clinical trials forward even if the
expected payoffs are low.
Our findings raise broader issues about the creation and survival of biopharma-
ceutical startups. If the R&D process in early stage firms is inefficient, as we suggest,
then it is natural to ask why such firms would ever be created and how they could
survive in parallel with mature biopharmaceutical firms that seem not to be plagued
by these inefficiencies. Why wouldn’t the founders of biopharmaceutical firms — most
of whom are academic scientists — sell their ideas to mature firms with diverse prod-
uct portfolios who can manage clinical development more efficiently? It is important
to note that many of them do in fact sell their scientific discoveries to established
firms. However, many do not because in doing so they give up control of follow-on
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scientific and clinical advances that emerge in the process of development. While a
scientist could, in principle, be compensated for these follow-on discoveries, given the
difficulty of writing complete contracts, it is unlikely that he would be compensated
as much as if he retained control and developed the idea in his own firm. Thus, one
potential benefit of founding a firm to commercialize a scientific discovery is that it
provides high-powered incentives for discovery. The potential cost — documented in
our research — is that it provides high-powered incentives to advance drugs through
clinical trials even though it may be inefficient to do so. This suggests that there are
costs and benefits of conducting scientific discovery within different organizational
forms. A fuller understanding of these costs and benefits should be the goal of future
research.
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1.6 Tables - Chapter 1
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Table 1.1: Sample Construction: Identifying Phase I Clinical Trial
The initial sample summarized in this table is from Roberts et. al. (2004). It is constructed
by searching for Phase I clinical trials listed in annual publications of Papers/Proceedings
of the American Society of Clinical Oncology from 1990-2002. For each year, the table lists
the number of abstracts identified, the number of abstracts eliminated from the sample
for each of the main reasons described in the text, the number of abstracts meeting the
selection criteria, and the number of unique drug agents meeting the selection criteria.
Number Abstracts Number of
of Meeting Unique
ASCO Chemo Combination Selection Agents
Year Abstracts Radiation -therapy Pediatrics Trials Criteria Names
1990 28 0 0 0 14 14 12
1991 142 3 4 4 62 73 20
1992 172 6 9 6 87 71 21
1993 196 13 7 7 111 76 27
1994 240 11 16 13 123 89 23
1995 162 14 8 4 90 67 26
1996 162 10 8 5 92 59 27
1997 263 25 19 9 112 113 39
1998 296 22 8 9 159 115 52
1999 282 25 12 5 160 112 34
2000 261 20 8 7 141 109 45
2001 282 19 2 4 120 149 29
2002 312 27 8 7 156 133 22
Total 2798 195 109 80 1427 1180 377
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Table 1.2: Time between Clinical Trials
This table reports data on the time that elapsed between the initiation of the first Phase I
clinical trial and the initiation of the first Phase II clinical trial for a particular agent, as
well as information on the time elapsed between Phase II and Phase III.
Panel A: Time Distribution between Clinical Phases (in months)
Mean Median 25% 75% St.Dev.
Phase I to Phase II 22.32 18 11 27 16.97
Phase II to Phase III 26.6 17 12 36 23.32
Panel B: Time between Clinical Phases
Phase I to Phase II Phase II to Phase III
Years Frequency Percentage Years Frequency Percentage
0-1 59 36.4% 0-1 10 20%
1-2 53 32.7% 1-2 20 40%
2-3 24 14.8% 2-3 8 16%
3-4 12 7.4% 3-4 4 8%
4-5 8 4.9% 4-5 3 6%
5-6 4 2.5% 5-6 3 6%
6-7 0 0.0% 6-7 1 2%
7-8 1 0.6% 7-8 0 0%
8-9 1 0.6% 8-9 0 0%
9-10 0 0.0% 9-10 0 0%
10-11 0 0.0% 10-11 1 2%
Total 162 Total 50
Panel C: Percentage of the sample moving to the next clinical phase
In 2 years In 3 years Ever
Phase I to Phase II 48% 58% 69%
Phase II to Phase III 19% 24% 31%
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Table 1.3: Agents per Company and Indications per Agent
This table reports summary statistics of the number of agents developed by companies and
the number of indications (different types of cancer) investigated for each drug developed.
Panel A: Number of Agents per Sponsor
Number of Agents Frequency Percentage
1 103 57%
2 43 24%
3 13 7%
4 7 4%
5 4 2%
6 5 3%
7 0 0%
8 2 1%
9 0 0%
10 1 1%
11 0 0%
12 0 0%
13 1 1%
14 0 0%
15 0 0%
16 2 1%
Total 181
Panel B: Number of Phase II Indications per Agent
Number of Indications Frequency Percentage
1 83 46%
2 31 17%
3 22 12%
4 14 8%
5 9 5%
6 9 5%
7 5 3%
8 3 2%
9 3 2%
14 1 1%
Total 180
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Table 1.4: Summary Statistics on Sample Companies
This table report summary statistics on the public companies in our sample. We use
Standard & Poor’s Compustat, Compustat Canada, and Compustat Global Indus-
trial/Commercial. For comparability, all the financial numbers are converted to million
U.S. Dollars deflated to the year 2000. All the figures are for the year in which each drug
went to Phase I clinical trials. Revenues, Assets, Cash, R&D, and Book Value are from
the respective items in Compustat. Market Cap is the number of outstanding shares at
the end of the calendar year multiplied by the share price at the end of the calendar year.
Q is defined as the ratio of the market value of equity plus the book value of assets less
the book value of equity to the book value of assets. Panel A reports the full sample;
Panel B reports the sub-sample of mature firms; and Panel C reports the complimentary
sub-sample of early-stage firms. We define an early stage firm as one with revenues less
than or equal to $30 million deflated to the year 2000.
Panel A: Number of Agents per Sponsor
Years Market Book
Statistics Public Revenues Assets Cash R&D Cap Value Q
Mean 25.8 8,116.90 10,964.50 1,947.00 1,003.90 38,635.20 5,282.30 10.2
Median 21.7 5,761.70 4,544.90 452.1 394.5 10,310.80 1,563.40 7.4
St. Dev. 22.7 9,766.10 13,531.10 3,257.80 1,228.80 54,844.10 7,001.90 10.5
1% 0.2 0 4 2.8 2.7 14.4 1.6 1.3
25% 4.2 9.5 57.5 41.4 21 202.7 45.7 4.4
75% 40.7 14,080.20 17,578.00 2,469.10 1,798.90 60,107.20 8,678.80 12.7
99% 73.4 33,822.00 45,561.80 12,959.50 4,879.30 246,316.30 26,140.60 64.4
Panel B: Mature Firms
Years Market Book
Statistics Public Revenues Assets Cash R&D Cap Value Q
Mean 37.4 14,178.90 19,084.50 3,340.10 1,736.80 67,134.80 9,172.70 10.5
Median 37.9 13,488.50 16,543.50 2,184.00 1,635.00 55,626.00 7,344.00 8.1
St. Dev. 21.4 8,982.50 12,874.00 3,745.60 1,175.60 57,889.40 7,092.60 7.3
1% 1.0 89.1 114.5 73.8 15 932.6 93.8 2.4
25% 24.0 7,683.00 9,288.80 775.5 847.9 23,310.10 4,557.50 6.5
75% 56.3 18,216.00 29,971.00 3,836.80 2,445.90 92,310.50 11,913.00 13.7
99% 73.5 37,899.10 47,542.30 15,602.20 4,879.30 246,316.30 26,140.60 35.8
Panel C: Early Stage Firms
Years Market Book
Statistics Public Revenues Assets Cash R&D Cap Value Q
Mean 10.2 10.7 106.3 84.1 23.9 404 78.9 9.7
Median 5 7.1 51.1 35.2 18.3 176.4 41.6 5.2
St. Dev. 12.9 11.6 156.9 142.1 26.3 581.4 120.3 13.8
1% 0.1 0 2.9 0.4 2.5 0.5 0.8 1.3
25% 1.3 1.8 24.9 17.8 10.4 72.4 18.1 3
75% 12 17.5 114.4 82.3 29.9 463.2 86.5 9.2
99% 42.4 28.1 793.7 788.5 223.5 2,893.80 541.4 74.2
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Table 1.5: Probit Regressions of the Probability of Moving from Phase I to Phase II
This table reports the result of probit regressions. The dependent variable takes the value 1 if the
firm progresses to Phase II trials within two years of initiating a Phase I trial and 0 otherwise.
The regressors include a dummy variable which takes the value one if the company is an early
stage company (revenues no more than $30 million deflated to the year 2000). The regressors also
include a set of controls for clinical results of the Phase I trials, as well as characteristics of the
drug in development. Response Rate I is the percentage of patients whose tumor shrank in the
Phase II trials. Toxicity is the percentage of patients who had a toxic reaction to the drug in the
Phase I trials. Biologic is a dummy variable that equals 1 if the drug is a biologic drug, 0 if it is
a chemical drug. NIH Sponsored is a dummy variable that equals 1 if the National Institutes of
Health (NIH) or any of its affiliate institutes such as the National Cancer Institute (NCI) sponsored
the drug. The regressions also control for the potential financial profit to be expected from the
development of the drugs. One of the controls is the PharmaProjects’ estimated market size of the
targeted indication. We use two dummy variables, one for whether the estimated market size is
between $500 million and $2000 million and another for whether the estimated market size exceeds
$2000 million. Another control measures the novelty of the drugs. We measure this by recording
the pharmacological description (a drug’s mechanism of action in the body through which it exerts
its therapeutic effect) and ranking the drug by the number of drugs developed for cancer with
the same pharmacological description prior to this drug. Novelty is the log of the inverse of this rank.
(1) (2) (3) (4)
Early Stage (dummy) 0.1613 0.1649 0.16 0.1655
(2.83) (3.17) (2.70) (3.01)
Response Rate I (percentage) 0.9721 1.1972
(0.90) (1.04)
Toxicity (percentage) -4.9275 -5.6069
(0.57) (0.59)
Biologic (dummy) -0.0274 -0.0668
(0.19) (0.41)
NIH Sponsored (dummy) 0.1929 0.2638
(1.14) (1.67)
Market Size - 500-2000$m (dummy) 0.2026 0.2005
(1.49) (1.43)
Market Size - 2000+$m (dummy) 0.0605 0.0499
(0.46) (0.37)
Novelty 0.0896 0.0957
(5.54) (5.45)
Number of Observations 235 235 235 235
Note: We report the change in the probability for an infinitesimal change in each independent,
continuous variable and, by default, the discrete change in the probability for dummy variables. In
parenthesis are the z-stats calculated using White (1982) standard errors. We cluster around the
phase I year.
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Table 1.6: Summary Statistics of Phase II Clinical Data
This table reports summary statistics on the clinical data collected from the Pa-
pers/Proceedings of the American Society of Clinical Oncology (ASCO) from 1990-2002.
If a drug had more than one Phase II trial for a particular indication we weight the
results by the number of effective patients in each clinical trial. There are 11 categories
of indications derived from the American Cancer Society. Response Rate is the per-
centage of patients whose tumor shrank in the Phase II trials. Previous Treatments is
the number of previous treatments the patients in the trial have had prior to joining the trial.
Panel A: Tumor Response Rates - Full Sample
Early Stage Mature
Response Rate Full Sample Companies Companies
Mean 0.095 0.061 0.12
Median 0.04 0.03 0.065
Std 0.133 0.076 0.159
% Greater than 0 67% 65% 70%
Panel B: Phase II Indications
Early Stage Mature
Indication Full Sample Companies Companies
Bone 1% 1% 0%
Brain & Nervous systems 3% 3% 3%
Breast 14% 10% 17%
Digestive 20% 22% 18%
Genital 14% 14% 14%
Head and Neck 3% 3% 3%
Leukemia 1% 2% 0%
Lymphoma 6% 7% 5%
Respiratory 20% 21% 20%
Skin 7% 8% 6%
Urinary 10% 7% 12%
Other 1% 0% 1%
Panel C: Trial Patients with Previous Treatments
Early
Previous Full Stage Mature
Treatments Sample Companies Companies
None 25.87% 25.58% 26.09%
1 21.39% 17.44% 24.35%
2 9.95% 10.47% 9.57%
2+ 41.29% 46.51% 37.39%
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Table 1.7: Regressions of the Response Rates of Patients in Phase II Clinical Trials
The dependent variable is Response Rate, the percentage of patients in a Phase II trial
whose tumors shrank. These data are taken from Papers/Proceedings of the American So-
ciety of Clinical Oncology (ASCO) from 1990-2002. If more than one trial was undertaken
for a certain indication, we average them, weighting by the number of patients. Because
indications have different baseline response rate, we control for each indication by including
indication dummies based on categories of the American Cancer Society. We also control
for the number of previous treatments the patients received prior to joining the trial, and
for the stage of the cancer the patient is in. Columns (1), (2), and (3) use the sub-sample of
public firms that moved to Phase II within 2 years of starting Phase I trials. Column (3) uses
the full sample. In parenthesis are the t-stats calculated using White (1982) standard errors.
(1) (2) (3) (4)
Early Stage (dummy) -0.0442 -0.0589 -0.0646 -0.0615
(1.44) (2.24) (2.38) (3.53)
Market Size - 500-2000$m (dummy) 0.0020 0.0502
(0.03) (1.12)
Market Size - 2000+$m (dummy) 0.0165 0.0340
(0.26) (0.96)
Novelty -0.0107 -0.0103
(2.05) (2.38)
Indication Dummies No Yes Yes Yes
Previous Treatment Dummies No Yes Yes Yes
Disease Stage Dummies No Yes Yes Yes
R2 0.02 0.29 0.3 0.27
Number of Observations 108 108 108 201
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Table 1.8: Probit Regressions of the Probability of Moving from Phase II to Phase
III for the Drugs Candidates that Moved to Phase II
This table reports the result of probit regressions. The dependent variable takes the value
1 if the firm progresses to Phase III trials within two years of initiating a Phase II trial
and 0 otherwise. The regressors include a dummy variable which takes the value one if
the company is an early stage company (revenues less than $30 million deflated to the
year 2000). The regressors also include a set of controls for the characteristics of the drug
in development. One of the controls is the PharmaProjects’ estimated market size of the
targeted indication. We use two dummy variables, one for whether the estimated market
size is between $500 million and $2000 million and another for whether the estimated
market size exceeds $2000 million. Another control measures the novelty of the drugs. We
measure this by recording the pharmacological description (a drug’s mechanism of action
in the body, through which it exerts its therapeutic effect) and ranking the drug by the
number of drugs developed for cancer with the same pharmacological description prior to
this drug. Novelty is the log of the inverse of this rank.
(1) (2)
Early Stage (dummy) -0.2136 -0.1931
(2.79) (2.46)
Market Size - 500-2000$m (dummy) 0.2057
(0.76)
Market Size - 2000+$m (dummy) 0.0276
(0.12)
Novelty 0.0618
(2.74)
Number of Observations 122 122
Note: We report the change in the probability for an infinitesimal change in each independent,
continuous variable and, by default, the discrete change in the probability for dummy variables. In
parenthesis are the z-stats calculated using White (1982) standard errors. We cluster around the
phase I year.
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Table 1.9: Probit Regressions of the Probability of Moving from Phase II to Phase
III for the Drugs Candidates that Moved to Phase II
This table reports the current status of the drugs in our sample according to PharmaPro-
jects. NDR - No Development Reported, is the status assigned by The PharmaProjects
when there is no information about a drug and it seems the drug is not under development
anymore (although the company has not officially announced that the drug has been
discontinued). Discontinued refers to drugs for which the company has announced that
it has ceased development. Pre-Registration refers to drugs for which the company is
in the process of filing a NDA (New Drug Application) with the FDA (Food and Drug
Administration) or has announced that it intends to do so . Launched drugs are those
drugs that have been approved by the FDA and are on the market. Panel A reports the
statistics for all the drugs; Panel B reports the statistics for the drugs that have moved to
Phase II within two years of Phase I initiation.
Panel A: All the Drugs
All Mature Companies Early Stage Companies
Status Frequency Percentage Frequency Percentage Frequency Percentage
NDR 53 22.55% 38 27.34% 15 15.63%
Discontinued 31 13.19% 22 15.83% 9 9.38%
Phase I 25 10.64% 15 10.79% 10 10.42%
Phase II 67 28.51% 27 19.42% 40 41.67%
Phase III 27 11.49% 16 11.51% 11 11.46%
Pre-Registration 5 2.13% 0 0.00% 5 5.21%
Launched 27 11.49% 21 15.11% 6 6.25%
235 139 96
Panel B: Drugs that Moved to Phase II in 2 Years or Less
All Mature Companies Early Stage Companies
Status Frequency Percentage Frequency Percentage Frequency Percentage
NDR 18 14.75% 9 14.29% 9 15.25%
Discontinued 12 9.84% 6 9.52% 6 10.17%
Phase I 1 0.82% 20 31.75% 1 1.69%
Phase II 44 36.07% 10 15.87% 24 40.68%
Phase III 20 16.39% 0 0.00% 10 16.95%
Pre-Registration 4 3.28% 0 0.00% 4 6.78%
Launched 23 18.85% 18 28.57% 5 8.47%
122 63 59
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Table 1.10: Sales of Approved Drugs
This table reports the sales of the drugs in the sample that were approved. The source of
the data is New Medicine’s Oncology KnowledgeBASE. All the sales figures are in Millions
of US Dollars deflated to year 2000 values. The numbers are for the first, second, and third
year of sales following FDA approval. Out of the 29 drugs approved in the sample, this
table is based on data on 23 of those drugs, 17 out of the 22 approved drugs originated by
mature companies and all the 7 approved drugs originated by early stage companies.
Mean Median St. Dev. Min Max
First Year Sales
Mature Companies 99.7 62.3 108.9 0.9 441.8
Early Stage Companies 12.7 6 17.1 1.4 56.4
Second Year Sales
Mature Companies 141.6 98.2 144.7 5 590.4
Early Stage Companies 60.3 15 72.9 2.6 176.1
Third Year Sales
Mature Companies 199.4 145.4 196 5 718.9
Early Stage Companies 108.5 20.8 135.6 6.5 339.4
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Table 1.11: Probit Regressions of the Probability of Moving from Phase I to Phase II
This table reports the result of probit regressions. The dependent variable takes the value 1 if the
firm progresses to Phase II trials within two years of initiating a Phase I trial and 0 otherwise.
The regressors include a dummy variable which takes the value one if the company is an early
stage company (revenues no more than $30 million deflated to the year 2000) and is financially
constrained (cash of less than $30 million deflated to the year 2000). We also include a dummy for
early stage companies that are not financially constrained (those early stage companies with more
that $30 million of cash deflated to the year 2000). The regressors also include a set of controls
for clinical results of the Phase I trials, as well as characteristics of the drug in development.
Response Rate I is the percentage of patients whose tumor shrank in the Phase II trials. Toxicity
is the percentage of patients who had a toxic reaction to the drug in the Phase I trials. Biologic
is a dummy variable that equals 1 if the drug is a biologic drug, 0 if it is a chemical drug. NIH
Sponsored is a dummy variable that equals 1 if the National Institutes of Health (NIH) or any
of its affiliate institutes such as the National Cancer Institute (NCI) sponsored the drug. The
regressions also control for the potential financial profit to be expected from the development
of the drugs. One of the controls is the PharmaProjects’ estimated market size of the targeted
indication. We use two dummy variables, one for whether the estimated market size is between
$500 million and $2000 million and another for whether the estimated market size exceeds $2000
million. Another control measures the novelty of the drugs. We measure this by recording the
pharmacological description (a drug’s mechanism of action in the body, through which it exerts
its therapeutic effect) and ranking the drug by the number of drugs developed for cancer with
the same pharmacological description prior to this drug. Novelty is the log of the inverse of this rank.
(1) (2) (3) (4)
Early Stage High Cash Firm (dummy) 0.3000 0.3165 0.2868 0.3029
(4.11) (4.50) (3.70) (4.00)
Early Stage Low Cash Firm (dummy) 0.0557 0.0508 0.0600 0.0609
(1.15) (1.21) (1.07) (1.10)
Response Rate (percentage) 1.0887 1.2828
(1.05) (1.15)
Toxicity (percentage) -7.6176 -7.7579
(0.87) (0.84)
Biologic (dummy) -0.0398 -0.0705
(0.30) (0.44)
NIH Sponsored (dummy) 0.1930 0.2558
(1.02) (1.49)
Market Size - 500-2000$m (dummy) 0.1634 0.1574
(1.06) (0.99)
Market Size - 2000+$m (dummy) 0.0072 -0.0071
(0.05) (0.05)
Novelty 0.0832 0.0881
(4.70) (4.46)
Number of Observations 235 235 235 235
Note: We report the change in the probability for an infinitesimal change in each independent,
continuous variable and, by default, the discrete change in the probability for dummy variables. In
parenthesis are the z-stats calculated using White (1982) standard errors. We cluster around the
phase I year.
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Table 1.12: Regressions of the Response Rate of Patients in Phase II Clinical Trials
The dependent variable is Response Rate, the percentage of patients in a Phase II trial
whose tumors shrank. These data are taken from Papers/Proceedings of the American So-
ciety of Clinical Oncology (ASCO) from 1990-2002. If more than one trial was undertaken
for a certain indication, we average them, weighting by the number of patients. Because
indications have different baseline response rate, we control for each indication by including
indication dummies based on categories of the American Cancer Society. We also control
for the number of previous treatments the patients received prior to joining the trial, and
for the stage of the cancer the patient is in. Columns (1), (2), and (3) use the sub-sample of
public firms that moved to Phase II within 2 years of starting Phase I trials. Column (3) uses
the full sample. In parenthesis are the t-stats calculated using White (1982) standard errors.
(1) (2) (3) (4)
Early Stage High Cash Firm (dummy) -0.0551 -0.0889 -0.0934 -0.0609
(1.73) (3.71) (4.20) (0.48)
Early Stage Low Cash Firm (dummy) -0.0364 -0.0397 -0.0466 -0.0147
(1.07) (1.33) (1.46) (1.50)
Market Size - 500-2000$m (dummy) -0.0138 0.0383
(0.20) (0.89)
Market Size - 2000+$m (dummy) 0.0000 0.0207
0.00 (0.59)
Novelty -0.0099 -0.0091
(2.25) (2.28)
Indication Dummies No Yes Yes Yes
Previous Treatment Dummies No Yes Yes Yes
Disease Stage Dummies No Yes Yes Yes
R2 0.02 0.3 0.31 0.28
Number of Observations 108 108 108 201
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Table 1.13: Probit Regressions of the Probability of Moving from Phase II to Phase
III
The model estimated is a probit model. The dependent variable is the probability of
advancing from phase II to phase III in the 3 years following phase II, thus it takes one
of two values: 1 if the drug moved to phase II and 0 if not. We define an early stage
company as one that has revenues (deflated to the year 2000) of less than 30$m. We
define a financially constrained company as one that has less than 30$m in cash and
short-term investments (Deflated to the year 2000). We regress this probability on a
dummy if the company is an early stage company and not financially constrained and on
another dummy if it is an early stage company that is financially constrained. Market
size - We use 3 dummies whether the potential market size is up to 500$m, between 500
and 2000$m and more than 2000$m. Novelty of the drugs - for every drug we record its
pharmacological description (a drug’s mechanism of action in the body, through which
it exerts its therapeutic effect) and rank the drug by the number of drugs developed for
cancer with the same pharmacological description prior to this drug. Novelty is the log of
the inverse of this rank.
(1) (2)
Early Stage High Cash Firm (dummy) -0.2974 -0.2903
(3.28) (3.54)
Early Stage Low Cash Firm (dummy) -0.0762 -0.0500
(1.02) (0.67)
Market Size - 500-2000$m (dummy) 0.3092
(1.14)
Market Size - 2000+$m (dummy) 0.0918
(0.46)
Novelty 0.0396
(1.66)
Number of Observations 122 122
Note: We report the change in the probability for an infinitesimal change in each independent,
continuous variable and, by default, the discrete change in the probability for dummy variables. In
parenthesis are the z-stats calculated using White (1982) standard errors. We cluster around the
phase I year.
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Table 1.14: Cox Proportional Hazard Model
We use a Cox proportional hazard model, following the specification outlined in Cox (1975) as a
methodology developed to analyze survival data. We do so in order to account for the possible right
censoring in our data. A drug is assumed to have a certain probability of succeeding in each period.
Success is defined as the event of moving from Phase I to Phase II, or the event of moving from
Phase II to Phase III. The instantaneous probability of success at any given time t is called the
hazard rate, h(t), defined as:
h(t) =
Probability of Success between t and ∆t
Probability of Success for times ≥ t
The Cox model assumes that the hazard function has a functional form, yet the model assumes no
restriction on the function. Thus, the dependent variable is time to the defined outcome. We use
the same variables and controls as described the earlier tables.
Advancing from Advancing from
Phase I to Phase II Phase II to Phase III
(1) (2) (3) (4)
Early Stage (dummy) 1.5790 0.3946
(3.43) (2.78)
Early Stage High Cash Firm (dummy) 2.2269 0.3452
(4.71) (2.88)
Early Stage Low Cash Firm (dummy) 1.2401 0.4487
(1.49) (1.76)
Response Rate (percentage) 0.0865 0.1112
(1.48) (1.34)
Biologic (dummy) 0.9413 1.0049
(0.22) (0.02)
NIH Sponsored (dummy) 1.8109 1.8232
(1.35) (1.27)
Market Size - 500-2000$m (dummy) 1.7818 1.5736 1.1652 1.2211
(1.61) (1.21) (0.22) (0.29)
Market Size - 2000+$m (dummy) 1.3730 1.1765 0.6158 0.6526
(0.97) (0.47) (0.61) (0.54)
Novelty 1.1246 1.0957 1.2773 1.2881
(1.80) (1.23) (1.55) (1.65)
Number of Observations 235 235 162 162
Note: We report the hazard rate for an infinitesimal change in time. In parenthesis are the z-stats
calculated using White (1982) standard errors.
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Chapter 2
Ownership vs. Contract: How
Vertical Integration Affects
Investment Decisions
2.1 Introduction
The costs and benefits of vertical integration have been the focus of much research
since Coase (1937) first raised the issue. Most of this research has been theoreti-
cal in nature1. There is a smaller empirical literature – summarized in Whinston
(2001) – that tries to test various theories by examining the causes of vertical in-
tegration. For example, researchers have examined whether firms that must make
relationship-specific investments are more likely to integrate (Joskow 1985, Baker
and Hubbard 2003) as suggested by a number of theories. There is, however, even
less empirical research on the effects of vertical integration, i.e. on how integration
affects firm behavior and performance. This literature has concentrated on the effect
of vertical integration across firms, comparing integrated and non-integrated firms
(Mullainathan and Scharfstein, 2001; Berger, et al., 2004). This work is an attempt
1Including the transaction cost approach of Williamson (1975, 1985) and Klein, Crawford and
Alchian (1978); the property rights approach of Grossman and Hart (1986), Hart and Moore (1990),
and Hart (1995); and the incentives-based models of Holmstrom and Milgrom (1991, 1994), Holm-
stro¨m and Tirole (1991), and Holmstro¨m (1999).
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to understand the effects of integration by performing a comparison of integrated and
non-integrated projects within the same firm. In particular, I examine R&D projects
that are fully integrated within a biopharmaceutical firm to those that are governed
through a contract with another firm.
I focus on the biopharmaceutical industry because large biopharmaceutical firms
are vertically integrated in that they perform R&D to develop new drugs, manufac-
ture the drugs, and market them. However, they are not completely integrated; while
developing their own drugs internally, they often contract with smaller biopharma-
ceutical firms to develop drugs as well. This feature of the industry enables me to
compare the management and performance of a set of projects that are governed by
ownership to those undertaken by the same firm that are governed by contract. This
allows me to examine the difference between transactions that occur within the firm
to those that occur between firms, the central issue raised by Coase (1937) and the
work of Williamson (1975), Grossman and Hart (1986), and Hart and Moore (1990).
The focus of the empirical analysis is on the clinical trials that are required for a
drug to be approved by the Food and Drug Administration (FDA)2. Drug candidates
must go through three phases of clinical trials on human subjects: small Phase I trials
designed in most cases to test a drug’s safety; larger Phase II trials to test both its
safety and efficacy; and finally very large Phase III trials with as many as a several
thousand subjects. At each point along the way, a company must decide based on
scientific, clinical, and financial information whether to continue to the next, more
expensive phase of clinical trials. These are the biggest investments companies make
in the R&D process.
The decision of whether to advance a drug candidate to the next phase of clinical
trials is the critical governance challenge in drug development. Ideally, this decision
would be based purely on scientific, clinical, and financial grounds. However, the
agent who is most closely involved in a drug’s development has a personal incentive
to move it forward even when scientific, clinical, and financial factors are not so
2The most recent estimate of the cost of getting a single drug approved is $802 million (deflated
to 2000). This estimate factors in the expected costs associated with failed attempts to develop a
drug.
55
promising. The incentive to continue to the next phase is very strong in the case
of a small, independent biopharmaceutical firm, because the agent owns the project.
Continuation of a project may signal to an imperfectly informed capital market that
the technology works, making it easier to raise additional capital. Discontinuation,
on the other hand, sends a very negative signal and could destroy the possibility of
raising funds in the future. Thus, the agent-owner has an incentive to continue a
project even when the scientific, clinical, or financial factors do not fully justify it.
By contrast, when an agent is running a project internally, the signaling value of
continuation is likely to be much weaker. In this case, the firm finances any future
projects of the agent. Unlike the external capital market, the firm itself is likely to
be well informed about the quality of the agent’s other projects. Thus, I argue that
these ”private benefits” of continuation are greater for non-integrated projects than
they are for integrated projects, and that this difference will give rise to differences
in the management and performance of the two types of projects.
In Section 2.2, I develop a simple theoretical framework to understand the effect
of these differences. I compare the optimal contract between a firm and an employee
(in the case of an integrated project) and the contract between the firm and an
entrepreneur (in the case of a non-integrated project). The key assumption is that
entrepreneurs derive greater private benefits from continuation than do managers
of internal projects. Integrated projects will be continued only if they are valuable
projects, while the contract governing non-integrated project will ex ante guarantee
continuation even in cases when the continuation is not warranted ex post. This
guarantee allows the entrepreneur to enjoy the private benefits of continuation. It
also acts as an incentive mechanism; the agent who owns the project enjoys the
continuation externalities and is thus motivated to exert more effort for the success
of the project. The result is that the optimal continuation probability of a non-
integrated project will be higher than that of an integrated project, while its average
ex post quality will be lower. The model also predicts that the continuation decision
for integrated projects will be more sensitive than the continuation decision for non-
integrated projects to changes in the financial resources of the firm.
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My empirical analysis compares the investment decisions of biopharmaceutical
firms with respect to their own (internal) projects to their investment decisions with
respect to alliance (external) projects. Alliance projects are projects that are devel-
oped and owned by a small firm, but a contract is signed with the large firm whereas
the large firm finances the project. The empirical evidence in this study is consistent
with the implications of the model. Controlling for firm and project characteristics,
alliance projects are 21% more likely to move from Phase I to Phase II, compared
to internal projects. However, alliance projects are less likely to eventually succeed.
I use two measures of success. One is whether the project moves from Phase II to
Phase III. In prior work, it has been shown that this decision is highly correlated with
the clinical results of Phase II trials (Guedj and Scharfstein, 2004). The other mea-
sure is whether the Phase III trials eventually receive FDA approval. On both counts
alliance projects are less successful. Alliance projects are 20% less likely to move from
Phase II to Phase III and they are 10% less likely to receive FDA approval. These
findings are consistent with the view that firms use a higher continuation threshold
on their internal projects than on their external projects.
Because internal and external projects could be fundamentally different in nature,
I control for an array of project and firm characteristics: the novelty of the drug
candidate (by looking at the number of drug projects that had used prior to it the
same mechanism to attempt to cure the same disease), the potential market size,
whether that drug candidate is of chemical or biological source, and the therapeutic
class this drug candidate belongs to. Unsurprisingly, more novel drugs have a higher
probability of advancing to the next phase and so do drugs with a higher potential
market size. However, none of these controls alter the results that internal projects
are less likely to advance to the next phase but eventually more likely to succeed.
Nevertheless, the results could be due to some unobserved heterogeneity in the
type of project. In order to investigate this possibility, I look at small firms that had a
contractual agreement with a larger firm, but were subsequently acquired by that large
firm. If there is an unobserved heterogeneity in the projects originated by the small
firm, this heterogeneity should continue to be present after the firm and its projects
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are fully integrated in the large firm. However, the probability of continuation of
projects that had been originated by the start up but were subsequently developed as
fully integrated projects by the acquiring firm, do not exhibit any differences neither
in their continuation decisions nor in their probability of success, compared to fully
integrated projects that had been initiated by the large firm. This result is another
indication that the level of integration affects investment decisions and performance,
and once the level of integration changes, so do the decisions.
This work relates to two empirical literatures. The first is the small empirical
literature on the effects of vertical integration. Mullainathan and Scharfstein (2001)
look at chemical producers that are integrated with the downstream users of their
chemical, and compare them with producers that are not integrated. They find
that the capacity of non-integrated producers is much more responsive to market
conditions than is the capacity of integrated producers. In fact, integrated firms
seem to hold more manufacturing capacity when it is least needed. Berger, et al.
(2004) compare small to large (integrated) banks. They provide evidence consistent
with small banks being better able to collect and act on soft information than large
banks. In particular, they show large banks are less willing to lend to informationally
”difficult” credits, such as firms with no financial records. These papers give an
indication that the level of integration can have an important effect on the decisions
firms make.
My findings are also related to the literature on the costs and benefits of internal
capital markets. Much of this literature suggests that internal capital markets lead
to investment inefficiencies due to cross-subsidization of divisions in low-growth in-
dustries by those in high growth industries (Scharfstein and Stein, 2000, Scharfstein,
1998, Shin and Stulz, 1998 and Rajan, Servaes and Zingales, 2000). Another line
of the empirical literature argues that internal capital markets enable firms to rede-
ploy capital from unprofitable sectors to more profitable ones (Guedj and Scharfstein,
2004; Khanna and Tice, 2001; and Maksimovic and Phillips, 2002). This paper shows
that in order for the firm to enjoy the benefits of an internal capital market, it needs
to own the project, and that financing investments through contracts does not give
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the firm the flexibility to properly redeploy its capital.
The remainder of the chapter proceeds as follows: in Section 2.2, I develop a simple
model to structure the problem that arises when bringing a non-integrated project
inside an internal capital market. In this section, I discuss the relevant empirical
implications of the framework to the biopharmaceutical industry. Section 2.3 gives a
short overview of alliances in the biopharmaceutical industry. Section 2.4 describes
the data, and Section 2.5 presents the results. Section 2.6 concludes.
2.2 A Simple Model
This section outlines a simple model for comparing a firm’s investment decisions
with respect to a project when it is governed by outright ownership and when it
is governed by a contract. Section 2.2.2 gives an interpretation the model in the
context of biopharmaceutical development and develops the empirical implications of
this framework.
The project has a life of two periods. At time t = 0 an investment I0 is made.
At time t = 1 uncertainty is resolved and the state of the world is observed. If the
project is continued, an investment of I1 is required. At time t = 2 the cash flows
materialize. There are two states of the world, Good (G) or Bad (B). The ex ante
probability of state G is θ and the ex ante probability of state B is (1 − θ). The
probability θ depends on the manager’s effort. The state of the world is observable
and verifiable. If the state of the world is B, the expected cash flow at time 2 is zero,
and thus the project is terminated at time 1. If the state of the world is G, there
are two possible outcomes. With probability α, a cash flow X is realized, and with
a probability of (1 − α) no cash flow is realized. α can be seen as a measure of the
quality of the project. α is random and can have one of two values, α ∈ {αL, αH},
where αH > αL. The probability of α = αH is p, and the probability of α = αL is
(1 − p). α is observable at time 1, but it is not verifiable and thus non-contractible.
See Figure 2-3 for a timeline of the model.
The project is initiated by a manager who is key to the development of the project.
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Thus, the manager needs to exert effort between time 0 and 1 in order to affect the
probability of getting to the good state of the world. The project manager receives
a payment w at time 2 if the project is successful. The manager chooses a level
of effort, θ, which increases the probability that the project is successful. However,
the manager incurs a personal, non-pecuniary cost, 1
2
βθ2, in doing so, where β > 0.
This effort choice cannot be observed by anyone and thus contracts cannot be made
contingent on it. It is also assumed that the manager has a “personal gain,” b, if her
project is continued at time 1, even if the project generates no cash flow at time 2.
For example, b could be thought of as a shock to the manager’s reputation, affecting
the value of her other projects that share the same technology.
I will use this personal gain or externality, b, to differentiate between internal
and external projects. When a project is internal, the manager has a low personal
gain from the project. However, when the manager owns the project she has a high
personal gain. When this personal gain is viewed as the externality received due to
the information about the general value of the manager’s projects, it is clear that if
the manager does not own the project she does not gain much from that externality.
Since the firm can observe the state of the world and the real value of the project, it
doesn’t need to continue a project in order to value the work of the manager. However,
when the manager owns the project, the informational value of continuation can be
quite high, for example, if the manager owns a start-up company with two projects,
one being developed and the other one needs funding. By having the first project
continued, a positive signal would be sent to the market about the potential value of
the second project, increasing the probability of securing funding for that project.
Regardless of the ownership of the project, it is assumed that the manager is
risk neutral and does not finance the project outside of the firm. In the case of
an independent entrepreneur, this model concentrates on the situation where the
financially constrained entrepreneur has elected to develop the project in alliance
with the firm. In order to simplify the analysis, it is assumed that, if possible, the
manager prefers to have her project financed by the firm.
Lemma 1 A compensation structure which pays contingent on success of the project
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(w2) dominates a compensation structure that pays contingent on the state of the
world (w1).
Proof 1
The firm:
E[piFirm]
= E[θ(α(X − w2)− w1 − I1)− I0 | α = αH ]
= p θ[αH(X − w2)− w1 − I1]
The manager:
E[U(piManager)]
= E[θ(αw2 + w1 + b)− 12βθ2 | α = αH ]
= p θ(αHw2 + w1 + b)− 12βθ2
Therefore, when ∂ E[U(pi
Manager)]
∂ θ
= 0
θ∗ =
p (αH w2 + w1 + b)
β
The firm:
E[piFirm |θ∗]
= p θ∗[αH(X − w2)− w1 − I1]
= [αHw2+w1+b][αH(X−w2)−w1−I1]
β
Therefore, when ∂ E[pi
Firm | θ∗]
∂ w1
= 0
w∗1 =
αH X − 2αH w2 − I1 − b
2
Therefore,
∂ E[piFirm | θ∗, w∗1]
∂ w2
> 0
Since the manager is financially constrained, w1 ≥ 0, thus, the only solution is such
that w1 = 0 and w2 > 0. 4
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There are several potential investment decisions the firm can make. The firm can
elect to always invest at time 1, to invest only if the state of the world is G, or only if
the state of the world is G and the realization of the quality of the project is α = αH .
Given the that the state of the world is observable and contractible, the firm will not
invest if the state of the world is B. However, if the state of the world is G, it can
always invest or only if α = αH . Since α is non-contractible, in this case the contract
must be set up so that it is in the interest of the firm ex post to make an investment
of I1 only when α turns out to be αH . By contrast, if the contract calls for the firm
to always invest in state G regardless of α, the payments do not need to insure that
it is ex post optimal for the firm to invest regardless of α.
In general, the contract can specify payments at time 0, time 1 conditional on
G or B. It can be shown that the optimal compensation is at time 2 conditional on
success as it fully aligns the manager’s incentives with the firm’s objective function.
Therefore, the firm can offer two different payments dependent on whether it plans
to always invest at time 1 or only if the realization of the quality of the project at
time 1 is α = αH .
2.2.1 Contracts
Contract 1 - Invest only if α = αH
This contract stipulates that at time 1, the firm will invest in the project only if it
observes that the state of the world is G and that the probability of a non-zero cash
flow at time 2 is αH . Thus, the firm will choose a payment wH such that:
max
wH
E[piFirm] = E[θ∗H(α(X − wH)− I1)− I0 | α = αH ] (2.1)
subject to
θ∗H ∈ argmax
θH
E[U(piManager)] = E[θH(αwH + b)− 1
2
βθ2 | α = αH ] (ICC)
E[U(piManager)] = E[θH(αwH + b)− 1
2
βθ2 | α = αH ] ≥ 0 (IRC)
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Therefore, the manager will optimize her effort level given the payment wH and the
firm will optimize the payment in order to increase the effort level θH . The result is:
θ∗H =
p(αHX − I1 + b)
2β
(2.2)
w∗H =
αHX − I1 − b
2αH
(2.3)
The payment w∗H meets the feasibility constraint:
w∗H ≤ X −
I1
αH
As one can see in equation (2.2), the manager’s effort increases with b. The more
the manager gains from the continuation of the project at time 1, the more the
manager will exert effort in order to reach the state G and increase the probability
of continuation. However, as equation (2.3) implies, the higher b is, the lower the
payment w needs to be for the principal to induce the manager to exert the same
level of effort. This is the basic insight of this model. When a manager owns her
project, a lower remuneration is needed in order to induce exertion of effort by the
manager. However, when a manager who needs to exert effort for the success of the
project does not own the project, the principal needs to pay a higher payment in
order to induce the manager to exert effort.
Contract 2 - Always Invest
This contract stipulates that at time 1, the firm will invest in the project regardless
of the realization α as long as the state of the world is G. Thus, the firm will choose
a payment wL such that:
max
wL
E[piFirm] = E[θ∗L(α(X − wL)− I1)− I0] (2.1b)
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subject to
θ∗L ∈ argmax
θL
E[U(piManager)] = E[θL(αwL + b)− 1
2
βθ2] (ICC)
E[U(piManager)] = E[θL(αwL + b)− 1
2
βθ2] ≥ 0 (IRC)
Therefore, the manager will optimize her effort level given the payment wL and the
firm will optimize the payment in order to increase the effort level θL. The result is:
θ∗L =
αX − I1 + b
2β
(2.2b)
w∗L =
αX − I1 − b
2α
(2.3b)
where α = pαH + (1− p)αL. The payment w∗L meets the feasibility constraint:
w∗L ≤ X −
I1
α
The basic results from the first contract hold in the same way with this contract. The
effort level θL increases with b and the manager’s payment decreases with b.
Which Contract Will be Preferred?
The second contract will be chosen if:
1) E[piFirm| contract 2] ≥ E[piFirm| contract 1] and
2) E[piManager| contract 2] ≥ E[piManager| contract 1].
This will happen if:
b ≥ I1 − αLX (2.4)
If the second contract is chosen, the effort the manager will exert θH will be higher
than the effort the manager would exert in case of the first contract θL:
θH − θL = (1− p)(αLX − I1 + b)
2β
(2.5)
64
which is always positive if the second contract is preferred.
The second contract will be chosen regardless of b if the project has a positive
NPV even when α = αL (i.e., when αLX − I1 > 0). However, when the project has
a negative NPV when α = αL, the decision of which contract to choose depends on
how large b is. If b is large enough, even projects with very negative NPVs will be
developed at time 1. This situation is solely due to the existence of this external gain
for the manager that allows in a sense to the firm to extract some of this gain by
lowering the manager’s payment.
2.2.2 Empirical Implications
This simple model generates several empirical implications regarding the investment
decision of the firm when it has both integrated and non-integrated projects. This
section develops the empirical implications in the context of the biopharmaceutical
industry. In the context of the biopharmaceutical industry, the timeline of the model
would be equivalent to engaging in Phase I (at time 0), deciding to move to Phase
II (at time 1), and getting FDA approval (at time 2). α is the equivalent of the
conditional probability of receiving FDA approval given that the project advanced to
Phase II.
Prediction 1 All else equal, the probability of a project advancing from Phase I to
Phase II will be higher for a non-integrated (alliance) project than for an integrated
(internal) project.
Regardless of the chosen contract, the effort level exerted by the manager increases
with b:
∂ θ∗
∂ b
> 0
Moreover, when b ≥ I1 − αLX, the second contract will be chosen for non-integrated
projects, while the first contract will be chosen for integrated projects. In such a case,
as equation (2.5) shows, the effort level will be higher since θH > θL.
Prediction 2 Non-integrated projects will have ex post a lower success rate than
integrated projects.
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When b ≥ I1−αLX the second contract will be chosen for alliance projects. The firm
will always invest in those projects at Phase II. Due to that, the average probability
of success of such projects will be equal to α = pαH + (1 − p)αL. However, internal
projects will always have the first form of contract, resulting in a probability of success
equal to αH . The higher b, the greater the probability that a project with α = αL
will be undertaken. The result is that cross sectionally, the average quality of an
alliance project (its α) will be lower than the average quality of an internal project,
since alliance projects will have a lower cutoff for continuation.
Prediction 3 The firm’s investment decisions regarding integrated projects compared
to non-integrated projects will be more sensitive to financial and human capital con-
straints, and will be more sensitive to the existence of other projects in the firm’s
portfolio.
The firm and the external entrepreneur have a binding contract. Until now I
have assumed that all the agreement are not open for renegotiation. The agreement
between the firm and its employee can be seen as somewhat different. This is not a
contract per se but an agreement where the firm commits to pay a certain payment.
If the firm chooses so, it could pay the payment wH and yet not continue a project, for
example if it is financially constrained. This flexibility, is another aspect of ownership.
As defined by Grossman and Hart (1986) this is one of the prerogative of the owner,
to have the control on any aspect that has not been given away in a contract. The
agreement between the owner and the employee does not stipulate continuation but
rather a certain wage in which it is in the interest of the firm ex post to make that
investment. However, if the firm’s interest are altered, as the rightful owner, it has
the flexibility not to invest.
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2.3 The Pharmaceutical Industry and Alliances -
Background
In this study I restrict my attention to the R&D of drug development in the pharma-
ceutical industry. There are a few reasons for this. First, due to regulation, detailed
data is available on project level decisions. Second, it is possible to compare different
projects inside the same firm, and across firms, since all drug development projects
have to follow the same stages and procedures. This creates a relative homogeneity
in the comparison of projects. Third, the outcomes of projects are measurable and
comparable. A successful project is one that receives FDA approval. Fourth, there
exists much heterogeneity in ownership structures of projects in this industry. Fifth,
the biopharmaceutical industry is a major industry in R&D expenditure. In 2000, it
accounted for 25% of all expenditure on R&D in the US.
This section gives a brief background on the industry and the mechanics of al-
liances.
2.3.1 The Drug Development Process
After a drug compound has been identified through pre-clinical research, the biggest
investments that biopharmaceutical firms make are the clinical trials they conduct
to prove the safety and efficacy of the drug candidate. In order to gain regulatory
approval for market introduction, the FDA requires that biopharmaceutical com-
panies provide substantial evidence of a drug’s effectiveness through adequate and
well-controlled clinical investigations. Proof of the drug’s effectiveness must be pro-
vided by the results of randomized controlled trials. These are comprised of three
main rounds of clinical trials on human subjects.
Phase I trials are typically conducted on fewer than 30 patients and are designed to
determine a drug’s safety. For most diseases, these trials are performed with healthy
subjects. DiMasi, et. al. (2003), using a sample of 68 drug candidates undergoing
trials at large biopharmaceutical firms between 1983 and 1994, estimate that the
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mean (median) out-of-pocket cost of a Phase I trial was $15.2 million ($13.9 million)
deflated to year 2000 US Dollar terms.
Phase II trials are larger and more costly than Phase I trials. They are conducted
on as many as a few hundred subjects, use patients with the disease, and are designed
to test both the safety and efficacy of the drug agent. The mean (median) cost of a
Phase II trial in the DiMasi, et. al. sample was $23.5 million ($17.0 million).
Finally, Phase III trials are typically very large studies, including possibly thou-
sands of subjects. The mean (median) cost of a Phase III trial in the sample was
$86.3 million ($62.0 million). After completing these trials, a drug sponsor can seek
regulatory approval from the FDA by filing a New Drug Application (NDA).
2.3.2 Alliances
Alliances are a common way for pharmaceutical firms to augment their drug pipeline;
they can be signed at any stage in the drug development process. Alliances signed at
an early stage (preclinical) are usually longer-term relationships. The main aspect is
the financing of the entire process. These alliances usually have a broad scope and
include most of the applications of an underlying technology. Alliances signed at mid
stage (during clinical trials) are somewhat different. The disease the drug is supposed
to cure is more defined and therefore the deal typically is narrower in scope. The
rationale behind late stage alliances has less to do with financing (as most of the cost
has already been incurred) and more to do with utilizing the marketing capabilities of
large pharmaceutical firms. Nicholson, Danzon, and McCullough (2003) analyze the
valuation of alliance deals showing that it is a vibrant and well performing market.
Figure 2-1 gives the distribution of alliances over time by the stage of signing. As
one can see, the number of alliances has increased over time. Large biopharmaceutical
firms are relying more on these alliances to supplement their own pipeline. Figure
2-2 details the alliance total cost by stages.
There are many ways to structure alliances. In general, however, most alliances
have the same components. Most pre-commercial payments to licensors can be al-
located to one or more of four categories: (1) upfront or licensing fees; (2) R&D
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payments; (3) milestone payments; and (4) equity3. Average upfront payments tend
to be larger the more advanced the stage of the alliance at signing (this is a way to
participate in the prior cost of research and development incurred by the licensor).
For clinical-stage alliances, R&D payments usually depend on the development of
the next generation or back-up compounds. “Milestone” is a general definition of
all event-contingent payments, including achievement of benchmarks associated with
a compound’s early or clinical development through first commercial sale, as well as
patent issuance. Equity is one of the less common components of an alliance, as many
do not include an equity investment.
Although each alliance is structured differently, the components are similar. How-
ever, alliances differ a lot depending on the stage at which they were signed. Therefore,
in this paper I will concentrate only on early-stage alliances in order to reduce the
variability of the different contracts and the effect it could have on the outcome of
the drug development process.
2.4 Data
2.4.1 Data Source
The main data used in this study is obtained from PJB Publications’ PharmaProjects.
The PharmaProjects is a UK based commercial database that tracks drug compounds
through their stages of development, from as early as pre-clinical laboratory studies to
FDA approval. This database is typically licensed by major pharmaceutical, biotech,
accounting, and law firms for the purpose of learning what the competition is doing.
Since clinical trials are performed by medical institutions that publish the results of
their research, the PharmaProjects is able to gather information on projects of both
public and private companies. In addition to identifying the drug and its sponsoring
organization, the PharmaProjects also gives information on the timeline of devel-
opment (including the dates of Phase I, Phase II, Phase III, and FDA approval or
3See Lerner and Malmendier (2004) for a thorough analysis of alliance contracts.
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discontinuation of the project). This database also provides detailed information on
the drug candidates, including the indication it is aimed to cure, its pharmacological
routes, its potential market value and of course the sponsoring firm. This data not
only allows tracking of drug candidates over time, it also allows building a time series
of each firm’s R&D portfolio and its pipeline of drugs.
Data on the alliances is obtained from the databases of Recombinant Capital
(ReCap), a San Francisco-based consulting firm specializing in tracking the biophar-
maceutical industry, and mostly the alliances between the companies in this industry.
As mentioned earlier, one advantage of studying biopharmaceutical firms is the de-
gree of disclosure in this industry. Publicly traded biopharmaceutical firms, like other
concerns, are required by the US Securities and Exchange Commission (SEC) to file
material documents. Biopharmaceutical companies tend to interpret this requirement
conservatively, and often file alliance contracts. This allows ReCap to gather infor-
mation about alliance contracts between various biopharmaceutical companies even
if one of them is a private company.
2.4.2 Data Sample
The empirical design of this study requires concentrating on firms that have both
internally and externally developed projects. For this purpose, I concentrate on the
40 largest public biopharmaceutical firms. I focus only on public firms for two main
reasons. The quality of information should be equivalent since they have to follow
the same disclosure rules. It also allows me to link the drug development data to
financial information from COMPUSTAT.
I extract from PharmaProjects all the drug development projects data that in-
volves any of those 40 firms and that have valid information. This results in 3610
projects initiated by 40 companies between the years 1984-2001. I do not gather
information on projects initiated after the year 2001 so as to have enough time to get
information on movement to phase II.
I also extract from ReCap information on projects where there was an alliance that
involved one of these 40 companies as the financing side of the alliance. I manually
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match these alliances with projects in PharmaProjects using the drug name, the
originator’s name and the start-up’s name. In this study I concentrated on alliances
signed before phase I. In particular, I eliminate alliances where:
• One of the parties is a university, medical center, non-profit organization, or
government agency.
• One of the parties has a controlling interest in the other, either through a
majority equity stake or through a purchase option (e.g., an alliance between a
firm and one of its R&D limited partnerships).
• More than two firms are involved, making the analysis less clean and tractable.
• The agreement as filed contains no information on the stage it which it was
signed.
• The alliance was signed after phase I had been initiated. The later the stage,
the less the alliance is about research and development, and the more it is about
combining marketing or manufacturing capabilities.
This results in 447 drug candidates. I will refer to projects originated by a firm as
internal and those that were originated by another company and the firm signed an
alliance on as an external project. All this results in 4057 drug development projects,
of which 3610 were internally developed and 447 were externally developed.
2.4.3 Summary Statistics
Information on Clinical Trials
The main focus of my analysis is the decision a firm makes whether (and when) to
advance a project from one phase to another. Table 2.1 Panel A reports the number
of projects and the percentage of projects in each phase. Table 2.1 Panel B reports
the distribution of the time between different phases. Since it takes some time to start
a new clinical phase, in the cases where the time to Phase II is less than one year, it
indicates that some or even all the preparations were undertaken before Phase I was
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finished. This implies that the decision was taken with no real regard to the clinical
data generated by Phase I. As table 2.1 Panel B indicates, the average time from the
beginning of a Phase I trial to the beginning of the first Phase II trial is 1.79 years.
The mean time from Phase II to Phase III is 2.4 years. These results are similar to
the results in DiMasi et. al. (2003).
Of course, not all trials move forward to the next phase. As table 2.1 Panel A
shows, only 71% of the internally developed projects advance from the pre-clinical
stage to Phase I. The figure regarding alliance projects is quite different, 93% of them
advance to Phase I. However, this is not surprising. This is not an unbiased sample
of all pre-clinical projects developed by startups. This is the subset of those projects
that generated enough interest for a large biopharmaceutical company to sign an
alliance on. It is not unreasonable to expect that such an agreement is signed with
the intent to advance to clinical trial. A caveat that must be noted is that since the
most reliable source of information about drugs for PharmaProjects is clinical trial
result, it is possible that if a drug was developed by a small private company that
never reached clinical trial it may not have been recorded. In such a case there would
have been no way to match it to an alliance agreement if one were available. Due
to all that, I will not look at the decision to advance to Phase I, but only at the
subsequent decisions that do not have those potential problems.
The other transition probabilities indicate the main results of this study. Internal
projects advance to Phase II with a probability of 70%, while external projects ad-
vance with a probability of 75%. They also do so at a much higher pace: 1.57 years
compared to 1.80 years. However, in the probability of advancing to Phase III the
order is reversed. Internal projects have a probability of 54% while external projects
advance only with a probability of 45%. The probability of success of an internal
project from Phase I to FDA approval is 22% while external project have a success
rate of 17%, even they got more chances by advancing to Phase II in higher numbers.
Control Variables
The analysis controls for important characteristics of the drugs in development.
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Table 2.2 reports the distribution of therapeutic classes across the different com-
pounds. A therapeutic class is the main disease the drug is aiming at. The therapeutic
activity codes are as defined in the Pharmaprojects Therapeutic Classification Sys-
tem (PTCS). This classification is based on the original classification devised by the
European Pharmaceutical Market Research Association (EPhMRA). The PTCS is
divided into fourteen major sections covering broad therapeutic areas, such as blood
and clotting products, anticancer agents or respiratory agents. This classification is
similar to the World Health Organization’s (WHO) typology used by Danzon, Nichol-
son, and Pereira (2003). As Danzon et. al. have shown, different therapeutic classes
carry different probabilities of success; it is thus important to control for those dif-
ferences. As one can see in table 2.2, there is a wide dispersion between internal and
external. Some of the smaller indications do not have alliance projects, mostly indi-
cating that these indications either require some unique expertise, or that the cost
cannot support the creation of a new company. In general, one can observe that firms
use alliances in most of the indications they develop drugs for, making it a widely
used tool for enhancing their pipeline.
Different compounds that aim at different diseases may also differ in their potential
financial value. Table 2.3 Panel A reports the distribution of the estimated potential
market size of each compound if eventually approved. These figures are estimated
by the PharmaProjects. There doesn’t seem to be a large difference in project types
between alliance and internal projects.
In order to control for the novelty of the compound I use the pharmacology of a
drug as described by Guedj and Scharfstein (2004). The pharmacology describes a
drug’s mechanism of action in the body, through which it exerts its therapeutic effect,
i.e. it identifies the biological agent or process the drug stimulates or inhibits. The
novelty ranking is based on the chronological use of a pharmacological mechanism for
a certain therapeutic class. Using the entire universe of compounds developed in the
past 20 years (both approved and discontinued compounds), I rank each compound by
the chronological appearance of its pharmacological mechanism and therapeutic class.
For example, compound A uses the mechanism ”Phosphodiesterase V inhibitor” and
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its development started in 1990, and compound B uses the same mechanism, but
its development started in 1991. Then, compound A will receive the rank 1 and
compound B will receive a rank of 2 and so on. This methodology gives a basic sense
of whether a compound uses a mechanism that is new or that has been previously
used. Table 2.3 Panel B describes of mean comparison of novelty of drugs between
internal and alliance projects. The mean rank of a drug developed by an early stage
drug is 24.07. While the mean rank of a drug developed by a mature company is
28.31. The difference is not statistically significant.
Information on Companies
Table 2.4 presents summary data (deflated to the year 2000 US Dollar terms) on
the public companies sponsoring the trials in the sample. On average, the public
companies are very large, with mean revenues of over $9 billion, mean assets of almost
$13 billion, mean cash of close to $2.2 billion and mean R&D of about $1 billion. The
average market capitalization is over $32 billion and the mean Q is 3.45. Nonetheless,
there is wide heterogeneity among the firms in the sample. This is mainly due to the
long time series, whereas most of the companies have grown over time to the large
size as indicated by the means. Some of the largest companies in the sample, are
the largest world drug manufacturers. With sales of more that $35 billion, R&D
expenditure of almost $3 billion and more than 100 thousand employees worldwide.
2.5 Empirical Analysis
In this section I compare the investment decisions firms make regarding projects
that are vertically integrated (internal projects) and projects that are not integrated
(external or alliance projects) but that are governed by a contract.
74
2.5.1 Analysis
Phase I to Phase II Transition Probabilities
All the projects in this analysis were either developed inside the firm from the earliest
stages (pre-clinical) or an alliance contract was signed prior to the beginning of Phase
I. However, it is reasonable to assume that if a contract was signed prior to Phase I,
there might have been an ex ante intent to move to Phase I. Due to this possibility,
in this work I will not concentrate on the decision to advance to Phase I, but rather
on the decision of whether to move to Phase II given that Phase I was completed.
As mentioned in section 2.4, Phase II is a large and expensive phase with a mean
cost of $23.5 million. Often, more than one Phase II is required, making it even more
expensive. Therefore, due to its potential cost, the decision to move from Phase I to
Phase II is an ideal setting to address the question of whether ownership has an effect
on the investment decisions of the firm.
The following analysis looks at the factors that affect whether a firm advances a
drug from Phase I to Phase II. This is aimed at testing Prediction 1 from section
2.2.2. The hypothesis of this prediction is that firms will be more likely to terminate
an internal project than an alliance project. All the tables reported are of a linear
probability estimation.
I do not estimate Probit models, because Maximum likelihood estimators in the
presence of fixed effects suffer from the ’incidental parameter problem’ as was first
analyzed by Neyman and Scott (1948). There is a vast literature such as Heckman
(1981) who shows that in a Probit regression with a small sample, the presence of
fixed effects might generate an upward bias in the estimation of β. This upward
bias is exacerbated the smaller the sample is compared to the number of fixed effects.
Although this sample is quite large, I report a linear model in order to have consistent
estimates. The results also hold very similarly when using a Probit model and when
using a Conditional Probit Model as suggested by Chamberlain (1980) and a Cox
proportional hazard model.
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In table 2.5, I report the results of the estimation of the following regression:
Pr[Advancing from Phase I to Phase II ] =
= α + β1Alliance+ β2Novelty + β3Bio+ β4LGMKT + β5SMMKT+
+
∑
i∈Company
1i +
∑
j∈Therapy
1j +
∑
k∈Y ear
1k + ² (2.6)
The dependent variable gets the value of 1 if the drug moved to Phase II within
two years of initiating Phase I and zero otherwise. I use a two year cutoff on Phase
II decisions for two main reasons. First, without a cutoff, Phase I trials that were
begun in the early part of the sample would be more likely to be taken forward. If
there is an over-representation of one type of ownership structure in the early period,
this would bias the findings. The second reason to use a time cutoff is to measure
the aggressiveness with which firms move forward in the clinical trials process. As
one can see in table 2.1, the mean time to move from Phase I to Phase II is 1.69
years and the median is 1.82 years. To avoid making seemingly arbitrary cutoffs, a
Cox proportional hazard model has been estimated (not reported) and yields similar
results. The results are robust to using different time cutoffs, for example Table 2.6
reports results using a 3 year cutoff.
The independent variables are: Alliance is a dummy variable that gets the values
of 1 if the project was originated by another company and is undertaken in alliance
with that company, and gets the value of 0 if it is an internal project. Novelty is a
measure whether the technology of the drug is new in treating that specific disease.
It is constructed by looking at all the compounds developed over time and their
pharmacological description (their mechanism of action). Each compound is ranked
chronologically by the group of compounds that use the same pharmacology for the
same therapeutic class. Bio is a dummy variable that receives the value of 1 if the
project is about a compound that is biologic. If the compound is of chemical origins
the dummy gets the value of 0. Two variables are used to control for the potential
market size of the drug. The PharmaProjects estimates the potential market size
of a drug. From this assessment I generate three dummies for Small, Medium, and
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Large market size (0-2$b, 2-5$b, and +5$b respectively). LGMKT is a dummy that
gets the value of 1 if the drug is potentioally teargetting a large market share; and
SMMKT receives a value of 1 if the drug is targetting a small market.Three fixed
effects are added: company fixed effects, therapeutic class fixed effects, and year fixed
effects.
The first column of Table 2.5 is a simple comparison of means. An alliance project
has a probability of moving from Phase I to Phase II in two years that is higher by
15.9% than an internal project. All the t-statistics in the table are based on robust
standard errors corrected for firm-level clustering.
One potential explanation for this result is that alliance projects are inherently
different. Those projects are developed by young start-up companies. For an entre-
preneur to start a start-up and receive venture funding, the idea behind the start-up
must have a high potential value. Moreover, one could speculate that the idea should
be original and novel enough to have a potential for competing with products from
well established firms. Therefore, one could reasonably hypothesize that alliance
projects are more novel and therefore it is not unreasonable for those companies to
be more aggressive regarding their decision to advance from Phase I to Phase II.
Column 2 of Table 2.5 adds a measure of novelty. This control does not change the
basic result, yet shows that indeed more novel drugs will have a higher propensity
to move to Phase II. Those start-ups are usually generically referred to as ’Biotech’
since a large majority of them use a biologic source (as opposed to a chemical source)
for their compounds. Since biologic and chemical compounds could be different, col-
umn 3 adds a dummy for whether the compound is of biologic source. Since biologic
compounds are relatively new, this adds another measure of novelty.
A second possible explanation for this finding could be that drugs developed by
start-ups aim at higher payoff markets (increasing Yi in the model). Column 4 adds
controls for the potential market size. Drug candidates with higher potential payoffs
have a higher propensity to move to Phase II, however, this doesn’t hinder on the
basic result that alliance projects are more likely to move to Phase II.
In order to control for other potential explanations for this result I add three
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sets of fixed effects: firm fixed-effects, therapeutic class fixed-effects, and year fixed-
effects. Company fixed effects are added in column 5. Different companies may have
different policies and different degrees of aggressiveness in pursuing clinical trials. I
add therapeutic class fixed-effects since different diseases carry different probabilities
of success (see for example Danzon, Nicholson, and Pereira (2003) for an analysis of
success probability by therapeutic class). Column 6 gives the results of the analysis
with therapeutic fixed effects, not materially altering the result. Year fixed effects
are added in column 5. As argued by Lerner, Shane, and Tsai (2003), in different
years there are different market conditions that may lead to renegotiations of alliance
contracts or cancelations of those contracts.
Column 7 summarizes the results including all the controls and fixed effects. The
estimated marginal effect of an alliance is 0.2104, indicating that an alliance project
is 21% more likely than an internal project to move forward from Phase I to Phase
II. Table 2.6 reports the results of the same regression but with a dependent variable
that uses a cutoff of 3 years. As one can see, the results are very similar, indicating
that the results are not due to the fact that alliance projects are developed faster.
Performance of the Projects that Advanced to Phase II
As Prediction 2 suggests, non-integrated projects should have a higher probability
of advancing from Phase I to Phase II, but the eventual success of these projects
should be lower than the success of integrated projects. I use two measures for the
probability of success of the projects: the probability of moving from Phase II to
Phase III, and the actual approval of the drug by the FDA.
There are several reasons I use the decision to advance from Phase II to Phase III
as a measure of success although it is a choice the firm makes. First, the mean cost of
a Phase III is estimated at $86.3 million, but the actual cost can escalate to hundreds
of millions of dollars depending on the therapeutic class and the number of times it
needs to be undertaken. Most Phase clinical trials III are done more than once and in
different countries in order to receive regulatory approval from each separate country.
This high cost reduces the incentive of a firm to advance a low quality compound.
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Second, as shown by Guedj and Scharfstein (2004), the decision to advance from
Phase II to Phase III is closely linked to clinical results at Phase II. This makes this
decision a good proxy for the quality of a compound. However, since FDA approval
is the ultimate measure of success of any drug development project, I will use it as a
second measure of quality.
Table 2.7 reports the results of the regression of the probability of advancing from
Phase II to Phase III within three years, given that the drug candidate was in Phase
II:
Pr[Advancing from Phase II to Phase III ] =
= α + β1Alliance+ β2Novelty + β3Bio+ β4LGMKT + β5SMMKT+
+
∑
i∈Company
1i +
∑
j∈Therapy
1j +
∑
k∈Y ear
1k + ² (2.7)
Similarly to the Phase II analysis, I use a three-year time cutoff on Phase III
decisions. The results are robust to different time cutoffs and to a non reported Cox
proportional hazard model analysis. Column 1 is a simple comparison of means. An
alliance project that advanced to Phase II has about 9% less chances to advance
to Phase III. The other columns represent the regression of this probability on the
same controls that were described in section 2.5.1. Controlling for the novelty of the
drug has quite a strong effect. More novel drugs have a 15% higher probability of
advancing to the next phase just due to their novelty. At that stage the potential
market size does not seem to play a large role in the firm’s decision. However, adding
the therapeutic class fixed effects makes a dramatic change. As mentioned earlier,
different diseases carry different degree of complication in the drug development and
also to some extent different costs in the clinical trials. By controlling for those
disparities one gets a clear picture of the success of internal versus external projects.
After controlling for project, company, and year characteristics, the probability of
advancing a project from Phase II to Phase III is 20.7% lower for an alliance project
than for an internally developed project. These results seem to indicate that having
reached a more costly and complicated decision point, there was a reassessment of the
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real quality of the projects leading to the discontinuation of lower quality projects.
If one accepts that the decision to advance from Phase II to Phase III is a proxy of
the quality of a project, then these results corroborate the prediction that the average
quality of alliance projects is lower than the average quality of internal projects.
The ultimate definition of quality of a drug in the biopharmaceutical industry is
whether a drug is approved by the FDA. In order to corroborate the above results,
I run a regression of the probability of getting eventual FDA approval for a drug
candidate that had a Phase III done:
Pr[Receiving FDA Approval | Undertaking a Phase III trial] =
= α + β1Alliance+ β2Novelty + β3Bio+ β4LGMKT + β5SMMKT+
+
∑
i∈Company
1i +
∑
j∈Therapy
1j +
∑
k∈Y ear
1k + ² (2.8)
Table 2.8 presents the regression analysis. Indeed, not only do non-integrated
projects advance with a lower probability to Phase III, but even those that do advance
to Phase III have a lower probability of eventually getting FDA approval. Column
1 gives a simple comparison of means. An alliance project has a 9% lower chance of
getting FDA approval than an internal project. This result holds using the standard
controls; corroborating Prediction 2 that the average quality of an alliance project,
as defined by it probability of success, is lower than the average quality of an internal
project.
Even if one does not accept that the decision to advance from Phase II to Phase
III is a proxy for quality, these results seem to indicate that the average quality of
alliance projects is lower than the average quality of internal projects. When the firm
decides at Phase II whether to advance to Phase III, it has more information than
when it makes the decision to advance from Phase I to Phase II. Thus, one should
expect this more informed decision to yield a better outcome, i.e. a higher probability
of getting FDA approval. The fact that the probability of getting FDA approval for
a non-integrated project is lower, indicates that indeed non-integrated projects are of
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lower quality.
2.5.2 Alternative Explanations
The empirical results are in line with the implications of the model in Section 2.2.
However, there considerably could be alternative explanations that would still be in
line with the results. The results could be due to two different sort of alternative
explanations. First, it could be due to problems in the data; either because of an
endogeneity or because of a selection problem. Second, there are three main compet-
ing alternative explanations: learning, diversification, or real-options. In this section
I will describe those explanations and compare them to the hypothesis developed in
Section 2.2.
A. Endogeneity
The most basic criticism of this work is whether there exist an endogeneity problem.
For that purpose all the regressions use a set of control to try and account for such a
possibility. The Novelty variable is an attempt to capture differences in novelty and
technology of the projects. The Bio variable account for differences due to different
formulations. The MarketSize variables try to deal with the potential idea that
different organizational forms target different parts of the distribution of payoffs of
drugs. The results would make sense if smaller firms targeted only ”blockbuster”
drugs, and thus were willing to endure lower probability of success. The fixed effects
help account for potential differences in companies, diseases, and years that could
affect the results.
However, there could still be two sources of endogeneity in the data. First, there
could be some unobserved heterogeneity that is not captured with the control vari-
ables. Second, the regression framework may not fully account for the differences in
the characteristics of projects. In order to deal with those two potential problems I
perform the following tests:
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A.1 Problem of Causal Inference
The problem of causal inference is a problem due to the fact that only one realization
of events is observed. In the case of this study we observe for a certain drug only one
realization, it is either developed internally or in alliance. If we had both realizations
we could compare them directly and answer unequivocally what is the affect or inte-
gration investment decisions. Since we only observe one possibility there is a concern
that there might be an endogeneity problem. In order to address that I perform a
matching analysis.
Table 2.9 reports the results of such a matching estimator as specified by Heckman,
Ichimura, and Todd (1998) and Abadie and Imbens (2002). Observations are matched
based on all observable characteristics:Novelty, Bio, Market Size, Therapeutic Class,
and Year. I use 4 matchings per observation in order to improve the statistical
reliability. Then the probability of advancing from Phase I to Phase II is compared
between the matched observations. All the estimators are bias corrected following
Rubin (1973a and 1973b) and Abadie and Imbens (2002). Panel A reports average
treatment effects. The average difference of the probability of advancing from Phase I
to Phase II for the matched sample is 0.2944, statistically significant at the 1% level.
This shows that once observations are matched by their characteristics the differences
in the probability of advancing from Phase I to Phase II still hold. Panel B reports
average treatment effects for the treated. Since there are many more observations of
internal projects than of alliance projects restricting ourselves only to the treated is
in order. In essence by doing so one matches for every alliance projects an internal
projects, this results with an even panel. The result sill holds, this weakens the results
by reducing the coefficient from 0.2944 to 0.2034, and the z-statistic from 9.81 to 6.40,
but this is the same result. Matched by observables, the probability of advancing from
Phase I to Phase II is higher for alliance projects compared to internal projects.
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A.2 Technology Differences - Acquisitions
One potential criticism of the results in section 2.5.1 is that the controls do not
account for something unique in the projects originated by the start-up companies.
For this criticism to hold, one should expect that whatever makes those projects
unique should still hold after the start-up is acquired by a larger firm.
Therefore, in order to corroborate the above results and in order to alleviate this
potential criticism, I track start-up firms that had an alliance with a mature firm and
subsequently were acquired by that mature firm4. I define an acquired project as a
project that was originated (or its technology was originated) by a start-up company.
The company was acquired and the clinical trials started after the company was
acquired. Table 2.10 reports the result of the regression of the probability of a project
advancing from Phase I to Phase II. All the projects in that sample are fully owned
by the firm, but a subset of them was originated by companies that eventually were
acquired by the firm. Column 1 is a comparison of means. The mean probability of
a project moving from Phase I to Phase II is not statistically significantly different if
the project was originated by a large firm or if it had been originated by a startup but
is now owned by the large firm. All these results hold with the regular sets of control
used in section 2.5.1. This seems to indicate that what drives the above results is
the organizational form governing the management of the project. Non-integrated
projects seem to be treated differently by the firm, a situation that seems to change
once the firm fully owns the project, making it fully integrated.
These results indicate that there seems to be something quite different in the
decision mechanism, when a firm makes an resource allocation decision relating to
integrated and non-integrated projects.
B. Alternative Explanations
There are three main compelling stories that potentially could explain the results in
the same way the contracting story put forward does:
4See Higgins and Rodriguez (2003) for an analysis of post alliance acquisitions.
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B.1 Learning
A possible explanation for the results could be that large firms knowingly choose to
continue a project even if it is not that good since they might gain spillover knowledge
and learn just from the exposure to a technology that the firm is not an expert on.
Jaffe (1986) and Gomes-Casseres, Jaffe, and Hagedoorn (2004) show that spillover of
knowledge is very strong when a project is inside a firm, even when the firm does
not necessarily own the project. Thus, if a firm wants to ”acquire” knowledge or to
let it trickle down in the organization, it might be willing to continued a project it
knows does not have hight probability of success but generates value in another way.
In such a case the firm might be willing to do that between Phase I and Phase II as
the cost is not too high and the project is valuable since it hasn’t been long in the
organization. The firm might be reluctant to continue do that after Phase II exactly
for the opposite reasons: high costs and most of the knowledge should have been
acquired by then.
Such a theory does not seem to fully fit the fact that even the decision to advance
from Phase II to Phase III does not seem to be fully efficient. Such a theory would
predict a very harsh discontinuation decision at Phase II. However, one could always
argue that since does not disprove this idea directly. In order to test this idea I develop
a measure to how much the form could ”learn” from having a project internalized in
the firm. I define a variable, Expertise, as a variable that receives the value of 1 if:
The firm had at least one drug approved in the preceding 3 years, or if the firm has at
the time of its decision, at least 2 other projects in Phase III in the same therapeutic
class. This dummy variable give a sense of whether the firm has experience in a
certain therapeutic class, which should indicate that it has less need to learn from a
project and thus should be more reluctant to continue a mediocre project since it has
less to gain from its continuation.
Table 2.11 reports the result of the regression of the probability of advancing
a project from Phase I to Phase II controlling for the Expertise of a firm. The
Expertise is statistically significant, indicating that there is indeed an impact to how
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much can a firm benefit indirectly from having a project. It shows that there is an
impact on the firm’s decision by how much it is likely to gain from the project. We can
see however that the impact from internal and alliance projects is different. Internal
projects will be more likely to be discontinued if a firm is an expert in a field while
internal projects will be more likely to be continued. This is indeed in line with the
idea of spillover. An alliance projects will be less likely to be continued if a firm knows
the area well, and has less to gain from mere continuation. However,m internally it
probably is an expert and thus the value of its internal projects is probably higher.
The interesting fact is that these result do not change the fact that alliance projects
are more likely to be continued, this seems to indicate that expertise and spillover,
thought influential do not drive the above results but only supplement it. This indeed
seems to show that spillover does not contradict the idea of the impact of contracts
but is complementing it.
B.2 Diversification
Another alternative potential explanation is that large firms sign alliances in order to
diversify their pipeline of drugs. In such a case they would be more likely to sign an
alliance if they are weak in a certain class of drugs. If indeed this is the case, firms
should be less likely to discontinue an alliance drug simply because it might hurt an
already weak division. This idea is similar to the expertise idea, but is different in
the sense that it stresses not that the firm could learn from the drug but that it may
need it just so as to ”satisfy” the stock market. Thus, if a firm is weak in a ceratin
class it may be willing to continue a lower quality project just in order to maintain
(even if it is for the short run) a ”diversified” drug pipeline.
In order to test this idea I develop a Concentration Index. This is essentially
the ratio of the number of projects in a specific therapeutic class to the total number
of projects the firm is undertaking. This is an attempt to measure to what extent
the results can be explained by the need to maintain a project in a therapeutic class
where the firm is weak. This index is calculated at the date a Phase I of a project is
initiated.
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Table 3.4 Panel A gives the summary statistics of this Concentration Index.
There does not seem to be any difference between the concentration of the firm in a
specific therapeutic class when it sign an alliance compared to initiating an internal
project. However, the median is lower for internal projects and the standard devia-
tions is much higher. This indicates that although on average there is no difference
the distribution of the concentration at the time of initiation is somewhat different.
Firms tend to sign alliances when they are weak in a certain class but not when the
do not have many projects. This is probably due to the facts that smaller firms, that
expect to learn from the larger firms in the process of the alliance, would be reluctant
to sign a contract with a firm that has no real experience in that class. It also seems
that when a large firm has many project in a class it will be less likely to need to sign
an alliance with a small firm.
Table 3.4 Panel B gives the results of a regression of the probability of advancing
from Phase I to Phase II controlling for the concentration of projects in the firm. High
concentration has a negative effect on the firm’s decision. The more concentrated a
firm is in an area the less likely it is to take a project forward in that area. However,
this reluctance is not different for internal and alliance projects. There is no statisti-
cally significant difference between the decision with respect to internal and alliance
projects. This indicates that although there is an effect to diversification, this effect
is not different for internal and alliance projects, showing that this cannot explain
the results the way that a contract theorem can.
2.6 Conclusion
In this paper I compare two different financial arrangements: projects financed by
internal funding, and Projects financed via a contractual alliance. Those two different
arrangements govern integrated and non-integrated project respectively. I document
that that biopharmaceutical firms use different criteria in their allocation of resources
when assessing integrated and non-integrated projects. The probability of a non-
integrated project that is governed by a contract to advance from Phase I to Phase II
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is 20% higher. However, the probability of those projects to advance from Phase II to
Phase III is 20% lower, and eventually they are 10% less likely to get FDA approval
if they undertake Phase III. I interpret this result of having a lower probability of
success as an indication of the project being of lower quality. These findings are
robust to a set of project and company characteristics and controls. These results
disappear once the non-integrated company is acquired by the larger firm.
It seems that the decision criteria employed by a firm when considering integrated
and non-integrated projects are different. Integrated projects are sensitive to the
amount of cash on hand and to the number of other unrelated projects in the firm.
Non-integrated projects, however, are much less sensitive to cash and are not sensitive
to the existence of other unrelated projects. All these results seem to indicate that
biopharmaceutical firms make their resource allocation decisions regarding integrated
projects in a manner reminiscent of “winner picking.” Given their financial constraint,
they seem to pick the projects that have a higher probability of performing better.
However, when dealings with non-integrated projects, it seems that the contract re-
duces the flexibility and latitude the firm has to terminate or even postpone a decision
regarding the continuation of a project. This lack of flexibility results in promoting
further non-integrated projects at the expense of better integrated projects. These
projects eventually do not perform as well, resulting in a lower success rate.
There are a number of ways in which I hope to build on this research. First,
since integrated projects are of higher quality than non-integrated project, it would
be very interesting to concentrate on the small company’s portfolio. How do projects
that the company out-licenses compare to projects the company decided not to out-
license. Do they differ in characteristics or in quality. If so, is the company selling
”lemons” in the contracts it out-licenses? This is a potential serious issue of adverse
selection. Conversely, the firm could elect to out-license only its better projects in
order to create a good reputation. In such a case the firm would be selling ”lemons”
not to the licensor but to the market.
Second, The theoretical framework in the model implies that in return for guaran-
teeing continuation the firm pays less than the cost of developing a project internally.
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This raises the question of comparing the cost of developing an R&D project. Is
integration more costly? If so, what are its other values?
Third, Guedj and Scharfstein (2004) have shown that young companies are ex-
cessively prone to continue projects when they have the financial resources to do so.
This paper shows that having such a project in an alliance with a larger firm does not
resolve this over-investment problem. Since it seems difficult to discipline a start-up’s
decision, there must be something valuable in those companies that entices either the
market or more established companies to invest in them. Therefore, these start-ups
have much lower success rates. Understanding the origin of the innovation of these
companies and what makes them seem valuable (at least ex ante) and yet makes them
not as successful is a very valuable question.
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2.7 Figures - Chapter 2
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Figure 2-1: Number of alliances in the BioPharmaceutical industry in the years 1988-
2002, grouped by the stage the alliance was signed at.
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Figure 2-2: Average total size of an alliance (in US Dollars) in the BioPharmaceutical
industry in the years 1988-2002, grouped by the stage the alliance was signed at.
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Figure 2-3: Timeline of the model.
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2.8 Tables - Chapter 2
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Table 2.1: Time and Probability of Advancing from One Phase to Another
This table reports the time and probability of moving from one development phase to
another. Panel A reports the number of drugs in the sample that moved from pre-clinical,
to Phase I, Phase II, Phase III, and eventual FDA approval. Panel II reports the mean,
median, and standard deviation of the time of moving from one phase to another. Time is
measured in years.
Panel A: Success rate
All Internal External
Number Advance Number Advance Number Advance
Rate Rate Rate
Number of Projects 4057 3610 447
Went to Phase 1 2985 73.6 % 2567 71.1 % 418 93.5 %
Went to Phase 2 2108 70.6 % 1794 69.9 % 331 79.2 %
Went to Phase 3 1112 52.8 % 970 54.1 % 142 42.9 %
FDA Approval 671 60.3 % 597 61.5 % 74 52.1 %
Panel B: Time to Next Stage (in years)
All Internal External
Time to Phase 1 Mean 0.70 0.68 0.82
Time to Phase 1 Median 1.10 1.10 1.08
Time to Phase 1 Std 0.53 0.53 0.48
Time to Phase 2 Mean 1.69 1.70 1.47
Time to Phase 2 Median 1.82 1.90 1.50
Time to Phase 2 Std 1.17 1.14 1.39
Time to Phase 3 Mean 2.40 2.38 2.51
Time to Phase 3 Median 2.60 2.60 2.60
Time to Phase 3 Std 1.10 1.10 1.16
Time to Approval Mean 2.91 2.88 3.10
Time to Approval Median 2.74 2.74 2.74
Time to Approval Std 1.02 1.00 1.13
Time to cancellation Mean 2.85 2.78 3.75
Time to cancellation Median 2.17 2.09 3.59
Time to cancellation Std 2.38 2.38 2.17
Clinical Time to Approval Mean 8.07 8.09 7.92
Clinical Time to Approval Median 8.88 8.88 8.95
Clinical Time to Approval Std 1.84 1.85 1.79
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Table 2.2: Therapeutic Classes
This table reports the breakdown of projects by therapeutic classes. The therapeutic
activity codes, as defined in the Pharmaprojects Therapeutic Classification System
(PTCS). This classification is based on the original classification devised by the European
Pharmaceutical Market Research Association (EPhMRA). The PTCS differs from the
EPhMRA classification in that it has been considerably revised to more accurately reflect
the types of products in R&D in 2004, rather than the marketed products of the 1970s.
The PTCS is divided into fourteen major sections covering broad therapeutic areas, such
as blood and clotting products, anticancer agents or respiratory agents. This classification
is similar to the World Health Organization’s (WHO) typology used by Danzon, Nicholson,
and Pereira (2003).
Therapeutic Class Total Internal External
Alimentary/Metabolic 348 286 62
Anti-infective 749 654 95
Anticancer 442 396 46
Antiparasitic 18 18 0
Blood/clotting 203 197 6
Cardiovascular 653 631 22
Dermatological 78 67 11
Genitourinary and Sex Hormones 112 99 13
Hormones excluding Sex Hormones 65 63 2
Immunological 71 56 15
Musculoskeletal 272 244 28
Neurological 735 636 99
Respiratory 292 250 42
Sensory 19 13 6
Total 4057 3610 447
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Table 2.3: Control Variables
This table reports summary statistics on two control variables used in this study.
Panel A reports the distribution of the potential market size of the drug projects in this
study, This distribution is based on assessments made by PharmaProjects.
Panel B reports data on the ”novelty” of the drugs developed. Novelty is defined using the
pharmacological description of the drugs. The pharmacology describes a drug’s mechanism
of action in the body, through which it exerts its therapeutic effect, i.e. it identifies the
biological agent or process the drug stimulates or inhibits. Panel B describes the mean
”rank” of each drug. Each drug is ranked in chronological order of appearance of its
pharmacological mechanism for its specific therapeutic class of in the sample of all the
compounds developed in the past 20 years as reported by PharmaProjects.
Panel A: Distribution of Estimated Project Potential Market Size
Market Size Internal Alliance
US$ 0-500 million 9.2 % 7.9 %
US$ 501-2000 million 29.8 % 33.8 %
US$ 2001-5000 million 35.5 % 37.1 %
US$ 5001-10000 million 16.1 % 9.1 %
Over US$ 10000 million 8.1 % 9.4 %
Panel B: Mean Rank of drug Novelty
Mean Median Std
Internal Projects 24.07 8 48.07
Alliance Projects 28.31 10 50.11
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Table 2.4: Summary Statistics on Sample Companies
This table reports summary statistics on the firms in the sample. The numbers are averages
of all the firm-year observations. Sales, assets, cash, market cap are in Millions of Dollars.
Number of employees is in thousands. Q is defined as the market value of equity the book
value of assets less the book value of equity divided by the book value of assets. All the
numbers are deflated to year 2000 Dollars.
Statistic Sales Assets Cash R&D Market Cap Q Employees
Mean 9,751.33 12,663.86 2,158.25 1,034.74 32,684.01 3.45 38.84
Median 8,030.59 10,952.53 1,314.33 934.27 27,952.96 3.51 42.22
Std 9,691.63 12,219.54 3,053.65 844.02 28,937.93 1.09 35.76
Max 35,198.89 42,362.05 12,629.75 2,945.42 106,737.00 6.71 136.61
Min 14.08 277.71 179.91 40.70 606.57 1.52 0.17
25% 1,029.82 2,318.71 485.73 279.91 5,918.06 2.74 4.25
75% 15,350.96 18,720.97 2,489.55 1,716.58 55,619.64 4.03 52.16
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Table 2.5: Regression of the Probability of Advancing from Phase I to Phase II
The model estimated is a linear probability regression. The dependent variable is the probability of
advancing from phase I to phase II in the 2 years following phase I. It takes the value of 1 if the drug
advanced to phase II and 0 if not. An alliance project is defined as a project that was originated by
another company and an alliance contract was signed. There are several controls: 1) Novelty - Each
compound has a pharmacological description (a drug’s mechanism of action in the body, through
which it exerts its therapeutic effect). Compounds are ranked by the number of drugs developed
for the same therapeutic class with the same pharmacological description over time. Novelty is the
log of the inverse of this rank. 2) Bio - a dummy that receives a value of 1 if the compound is
based on a biologic agent and 0 if not. 3) Market Size - There are three dummies as defined by The
PharmaProjects: market size is up to 2000$m, between 2000 and 5000$m and more than 5000$m.
4) Three fixed effects: company fixed effects, therapeutic class fixed effects and year fixed effects.
The t-statistics, reported in parentheses, are based on robust standard errors that are corrected for
firm-level clustering.
(1) (2) (3) (4) (5) (6) (7)
Alliance 0.1591 0.1621 0.1763 0.197 0.1951 0.1969 0.2074
(7.71)*** (5.69)*** (5.43)*** (5.02)*** (5.19)*** (5.12)*** (4.68)***
Novelty 0.0255 0.0256 0.0272 0.0304 0.0297 0.0289
(2.24)** (2.28)** (2.45)** (2.61)** (2.51)** (2.55)**
Bio 0.0778 0.0817 0.0700 0.0735 0.0772
(2.46)** (2.51)** (2.32)** (2.34)** (2.37)**
Market Size - Large 0.0397 0.0666 0.0582 0.1535
(0.30) (0.50) (2.33)** (2.42)**
Market Size - Small -0.0532 -0.045 -0.0426 -0.0279
(2.20)** (1.96)* (1.72)* (1.32)
Observations 2985 2985 2985 2985 2985 2985 2985
R2 0.10 0.11 0.11 0.11 0.14 0.15 0.25
Company FE No No No No Yes Yes Yes
Therapeutic Class FE No No No No No Yes Yes
Year FE No No No No No No Yes
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Table 2.6: Regression of the Probability of Advancing from Phase I to Phase II - 3
Year Cutoff
The model estimated is a linear probability regression. This model is identical to table 2.5 expect for
a variation on the dependent variable. The dependent variable is the probability of advancing from
phase I to phase II in the 3 years following phase I. It takes the value of 1 if the drug advanced to phase
II and 0 if not. An alliance project is defined as a project that was originated by another company
and an alliance contract was signed. There are several controls: 1) Novelty - Each compound
has a pharmacological description (a drug’s mechanism of action in the body, through which it
exerts its therapeutic effect). Compounds are ranked by the number of drugs developed for the
same therapeutic class with the same pharmacological description over time. Novelty is the log of
the inverse of this rank. 2) Bio - a dummy that receives a value of 1 if the compound is based
on a biologic agent and 0 if not. 3) Market Size - There are three dummies as defined by The
PharmaProjects: market size is up to 2000$m, between 2000 and 5000$m and more than 5000$m.
4) Three fixed effects: company fixed effects, therapeutic class fixed effects and year fixed effects.
The t-statistics, reported in parentheses, are based on robust standard errors that are corrected for
firm-level clustering.
(1) (2) (3) (4) (5) (6) (7)
Alliance 0.1399 0.1518 0.1622 0.1713 0.1856 0.1911 0.2007
(6.01)*** (5.60)*** (5.52)*** (4.96)*** (5.01)*** (4.92)*** (4.42)***
Novelty 0.0256 0.0261 0.0256 0.023 0.021 0.0199
(2.40)** (2.30)** (2.25)** (2.22)** (2.02)** (1.97)*
Bio 0.0298 0.031 0.0301 0.0295 0.0313
(2.30)** (2.36)** (2.28)** (2.30)** (2.32)**
Market Size - Large 0.0233 0.0152 0.017 0.0465
(1.20) (1.12) (2.30)** (2.51)**
Market Size - Small -0.0176 -0.0167 -0.0028 -0.0153
(0.96) (0.96) (0.14) (0.94)
Observations 2892 2892 2892 2892 2892 2892 2892
R2 0.09 0.14 0.14 0.14 0.15 0.16 0.23
Company FE No No No No Yes Yes Yes
Therapeutic Class FE No No No No No Yes Yes
Year FE No No No No No No Yes
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Table 2.7: Regression of the Probability of Advancing from Phase II to Phase III
The model estimated is a linear probability regression. The dependent variable is the probability
of advancing from phase II to phase III in the 3 years following phase I. It takes the value of 1 if
the drug advanced to phase II and 0 if not. An alliance project is defined as a project that was
originated by another company and an alliance contract was signed. There are several controls:
1) Novelty - Each compound has a pharmacological description (a drug’s mechanism of action in
the body, through which it exerts its therapeutic effect). Compounds are ranked by the number
of drugs developed for the same therapeutic class with the same pharmacological description over
time. Novelty is the log of the inverse of this rank. 2) Bio - a dummy that receives a value of 1 if the
compound is based on a biologic agent and 0 if not. 3) Market Size - There are three dummies as
defined by The PharmaProjects: market size is up to 2000$m, between 2000 and 5000$m and more
than 5000$m. 4) Three fixed effects: company fixed effects, therapeutic class fixed effects and year
fixed effects. The t-statistics, reported in parentheses, are based on robust standard errors that are
corrected for firm-level clustering.
(1) (2) (3) (4) (5) (6) (7)
Alliance -0.0894 -0.1021 -0.0956 -0.1048 -0.1276 -0.1462 -0.1742
(2.49)** (2.52)** (2.96)*** (3.47)*** (3.45)*** (3.54)*** (3.90)***
Novelty 0.0563 0.0744 0.0545 0.1001 0.1313 0.1520
(2.29)** (2.37)** (2.42)** (2.52)** (2.96)*** (2.60)**
Bio -0.0571 -0.0457 -0.0605 -0.0617 -0.0562
(1.21) (1.12) (1.08) (1.10) (1.05)
Market Size - Large 0.0239 0.0325 0.0386 0.0297
(1.25) (1.27) (1.32) (1.28)
Market Size - Small -0.0282 -0.0179 -0.0025 -0.0095
(0.90) (0.84) (0.10) (0.50)
Observations 2108 2108 2108 2108 2108 2108 2108
R2 0.08 0.08 0.09 0.09 0.13 0.23 0.28
Company FE No No No No Yes Yes Yes
Therapeutic Class FE No No No No No Yes Yes
Year FE No No No No No No Yes
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Table 2.8: Regression of the Probability of Getting FDA Approval if Moved to Phase
III
The model estimated is a linear probability regression. The dependent variable is the probability of
receiving FDA approval in the 4 years following Phase III. It takes the value of 1 if the drug received
FDA approval and 0 if not. An alliance project is defined as a project that was originated by
another company and an alliance contract was signed. There are several controls: 1) Novelty - Each
compound has a pharmacological description (a drug’s mechanism of action in the body, through
which it exerts its therapeutic effect). Compounds are ranked by the number of drugs developed
for the same therapeutic class with the same pharmacological description over time. Novelty is the
log of the inverse of this rank. 2) Bio - a dummy that receives a value of 1 if the compound is
based on a biologic agent and 0 if not. 3) Market Size - There are three dummies as defined by The
PharmaProjects: market size is up to 2000$m, between 2000 and 5000$m and more than 5000$m.
4) Three fixed effects: company fixed effects, therapeutic class fixed effects and year fixed effects.
The t-statistics, reported in parentheses, are based on robust standard errors that are corrected for
firm-level clustering.
(1) (2) (3) (4) (5) (6) (7)
Alliance -0.0929 -0.0961 -0.0913 -0.0953 -0.105 -0.1133 -0.1089
(2.09)** (2.06)** (2.18)** (2.21)** (2.54)** (2.34)** (3.10)***
Novelty -0.0753 -0.0779 -0.0716 -0.0787 0.0364 -0.1016
(0.63) (0.31) (0.57) (0.61) (0.27) (1.16)
Bio -0.1179 -0.1238 -0.1061 -0.1114 -0.1170
(1.76)* (1.79)* (1.61) (1.30) (1.19)
Market Size - Large 0.0479 0.0759 0.1715 0.0476
(1.95)* (1.27) (1.35) (1.21)
Market Size - Small 0.017 0.0181 0.0138 0.0244
(0.55) (0.58) (0.40) (0.79)
Observations 1112 1112 1112 1112 1112 1112 1112
R2 0.08 0.10 0.11 0.11 0.13 0.15 0.16
Company FE No No No No Yes Yes Yes
Therapeutic Class FE No No No No No Yes Yes
Year FE No No No No No No Yes
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Table 2.9: Matching Estimators - Probability of Advancing from Phase I to Phase II
This table reports the results of a matching estimator as specified by Heckman,
Ichimura, and Todd (1998) and Abadie and Imbens (2002). Observations are matched
based on all observable characteristics:Novelty, Bio, Market Size, Therapeutic Class,
and Year. I use 4 matchings per observation in order to improve the statistical re-
liability. Then the probability of advancing from Phase I to Phase II is compared
between the matched observations. Panel A reports average treatment effects and
Panel B reports average treatment effects for the treated. All the estimators are bias
corrected following Rubin (1973a and 1973b) and Abadie and Imbens (2002).
Panel A: Average Treatment Effect
Coef. Std. Err. z stat P > |z|
0.2944 0.300 9.81 0.0000
Panel B: Average Treatment Effect for the Treated
Coef. Std. Err. z stat P > |z|
0.2034 0.318 6.40 0.0000
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Table 2.10: Regression of the Probability of Advancing from Phase I to Phase II -
Acquisitions
The model estimated is a linear probability regression. The dependent variable is the probability
of advancing from phase I to phase II in the 2 years following phase I. It takes the value of 1 if the
drug advanced to phase II and 0 if not. An acquired project is a project that belonged to a smaller
firm (that had in the past a contractual alliance with the larger firm) but subsequently got acquired
by the larger firm. There are several controls: 1) Novelty - Each compound has a pharmacological
description (a drug’s mechanism of action in the body, through which it exerts its therapeutic effect).
Compounds are ranked by the number of drugs developed for the same therapeutic class with the
same pharmacological description over time. Novelty is the log of the inverse of this rank. 2) Bio -
a dummy that receives a value of 1 if the compound is based on a biologic agent and 0 if not. 3)
Market Size - There are three dummies as defined by The PharmaProjects: market size is up to
2000$m, between 2000 and 5000$m and more than 5000$m. 4) Three fixed effects: company fixed
effects, therapeutic class fixed effects and year fixed effects. The t-statistics, reported in parentheses,
are based on robust standard errors that are corrected for firm-level clustering.
(1) (2) (3) (4) (5) (6) (7)
Alliance Acquisition -0.0104 -0.0085 -0.0099 -0.0098 -0.0119 -0.0147 -0.0202
(0.49) (0.39) (0.45) (0.45) (0.48) (0.60) (0.96)
Novelty 0.0403 0.0401 0.0425 0.0468 0.0454 0.0322
(3.40)*** (3.43)*** (3.75)*** (3.95)*** (3.80)*** (3.61)***
Bio 0.0738 0.0775 0.0664 0.0697 0.0732
(2.41)** (2.56)** (2.42)** (2.30)** (2.25)**
Market Size - Large 0.4150 0.05987 0.06875 0.0824
(0.50) (0.72) (1.33) (1.74)*
Market Size - Small -0.0732 -0.0677 -0.068 -0.0468
(2.75)*** (2.66)** (2.43)** (2.16)**
Observations 2567 2567 2567 2567 2567 2567 2567
R2 0.00 0.01 0.02 0.02 0.05 0.07 0.12
Company FE No No No No Yes Yes Yes
Therapeutic Class FE No No No No No Yes Yes
Year FE No No No No No No Yes
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Table 2.11: Regression of the Probability of Advancing from Phase I to Phase II -
Expertise
The model estimated is a linear probability regression. The dependent variable is the probability
of advancing from phase I to phase II in the 2 years following phase I. It takes the value of 1
if the drug advanced to phase II and 0 if not. There are several controls: 1) Novelty - Each
compound has a pharmacological description (a drug’s mechanism of action in the body, through
which it exerts its therapeutic effect). Compounds are ranked by the number of drugs developed
for the same therapeutic class with the same pharmacological description over time. Novelty is
the log of the inverse of this rank. 2) Bio - a dummy that receives a value of 1 if the compound
is based on a biologic agent and 0 if not. 3) Market Size - There are three dummies as defined
by The PharmaProjects: market size is up to 2000$m, between 2000 and 5000$m and more than
5000$m. 4) Three fixed effects: company fixed effects, therapeutic class fixed effects and year fixed
effects. Expertise is a dummy variable that receives the value of 1 if the firm is an ”expert” in the
therapeutic class of the project and 0 otherwise. A firm is defined as an expert if: 1) It had at
least one drug approved in the 3 years prior to the project’s Phase I date, or 2) It had at the time
of the project’s Phase I date at least 2 other projects in Phase III in the same therapeutic class.
The t-statistics, reported in parentheses, are based on robust standard errors that are corrected for
firm-level clustering.
(1) (2) (3) (4) (5)
Alliance 0.1591 0.197 0.2074 0.2011 0.2232
(7.71)*** (5.02)*** (4.68)*** (5.76)*** (5.24)***
Novelty 0.0272 0.0289 0.0216 0.0317
(2.45)** (2.55)** (2.32)** (2.51)**
Bio 0.0817 0.0772 0.0764 0.0744
(2.51)** (2.37)** (2.38)** (2.29)**
Market Size - Large 0.0397 0.1535 0.0378 0.1425
(0.30) (2.42)** (1.86)* (2.28)**
Market Size - Small -0.0532 -0.0279 -0.0485 -0.0212
(2.20)** (1.32) (2.08)** (1.21)
Expertise 0.0192 0.0011
(3.75)*** (2.05)**
Expertise*Alliance -0.0447 -0.0446
(2.93)*** (2.55)**
Observations 2985 2985 2985 2985 2985
R2 0.10 0.11 0.25 0.12 0.25
Company FE No No Yes No Yes
Therapeutic Class FE No No Yes No Yes
Year FE No No Yes No Yes
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Table 2.12: Regression of the Probability of Advancing from Phase I to Phase II -
Diversification
The model estimated is a linear probability regression. The dependent variable is the probability
of advancing from phase I to phase II in the 2 years following phase I. It takes the value of 1 if
the drug advanced to phase II and 0 if not. There are several controls as described in Table 2.5.
Concentration is a dummy variable that receives the value of 1the ration of projects in a specific
therapeutic class to the total number of projects the firm is undertaking. Panel A reports summary
statistics for the concentration variable. Panel B reports the regression. The t-statistics, reported
in parentheses, are based on robust standard errors that are corrected for firm-level clustering.
Panel A: Summary Statistics
Mean Median StD
Internal 0.1264 0.9097 0.6310
Alliance 0.1241 0.1111 0.2431
Panel B: Regression
(1) (2) (3) (4) (5)
Alliance 0.1591 0.197 0.2074 0.2145 0.2381
(7.71)*** (5.02)*** (4.68)*** (5.44)*** (5.30)***
Novelty 0.0272 0.0289 0.0208 0.0322
(2.45)** (2.55)** (2.29)** (2.41)**
Bio 0.0817 0.0772 0.0761 0.0722
(2.51)** (2.37)** (2.41)** (2.35)**
Market Size - Large 0.0397 0.1535 0.0377 0.1521
(0.30) (2.42)** (1.86)* (2.32)**
Market Size - Small -0.0532 -0.0279 -0.0485 -0.0224
(2.20)** (1.32) (2.08)** (1.89)*
Concentration -0.0875 -0.0675
(3.21)*** (3.32)***
Concentration*Alliance -0.0021 -0.0038
(0.43) (0.51)
Observations 2985 2985 2985 2985 2985
R2 0.10 0.11 0.25 0.12 0.25
Company FE No No Yes No Yes
Therapeutic Class FE No No Yes No Yes
Year FE No No Yes No Yes
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Chapter 3
Integration, Diversification, and
Financial constraints
3.1 Introduction
One of the central questions to receive a vast amount of research in corporate fi-
nance is the question of the effect of diversification, i.e. investment spillover across
various business units of multi segmented firms. The main question is, in the pres-
ence of financial constraints, to what extent does one segment’s performance affect
the investment decisions of the firm in other segments, whether related or not. This
question is a part of the larger debate on the cash-flow investment sensitivity started
by Meyer and Kuh (1957) and Modigliani and Miller (1958). This issue has become
a heated debate ever since Fazzari, Hubbard, and Petersen (1988).
Fazzari, Hubbard, and Petersen (1988) show that low-dividend-paying firms rely
more heavily on cash flow. Fazzari and Petersen (1993) find that these same firms
smooth their cash-flow fluctuations by using working-capital adjustments rather than
external financing to maintain desired capital spending. From a free-cash-flow point
of view, Lang, Stulz, and Walkling (1991) find that stock returns in corporate ac-
quisition transactions are negatively related to free cash flow for bidder firms with
poor investment opportunities. However, Kaplan and Zingales (1997) challenge this
literature by presenting opposing evidence from the low dividend payout subset of the
Fazzari, Hubbard, and Petersen 1970-84 sample. They show that within this sample
of low dividend payout firms, the least constrained ones have the highest estimated
sensitivity.
Moreover, firms operating in multiple lines of business tend to have lower values
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than portfolios of similar firm (Berger and Ofek (1995), Lang and Stulz (1994), and
Servaes (1996)). One explanation for this diversification discount is an inefficiency in
the internal capital markets: good segment cross-subsidize the bad segments. Berger
and Ofek (1995) find that diversified firms overinvest in segments with poor invest-
ment opportunities. Lamont (1997) finds that oil companies reduced investment in
their otherwise unrelated non-oil segments in response to the 1986 oil shock. Shin
and Stultz (1998) analyze segment-level investment behavior and document high sen-
sitivity on the part of small segments to cash flow generated by other segments.
Scharfstein (1998) finds that diversified firms overinvest in low Q segments.
The pharmaceutical industry is an ideal setting to test such related issues. Most
large firms do not concentrate on one disease (such as cancer) but develop simultane-
ously drug candidate in various different classes of diseases. Some classes of disease
are very related, for example cancer, HIV, and rheumatoid-arthritis drugs are very re-
lated as they all are immuno-suppressants. However, the expertise needed to develop
a drug in some disease classes has very little to teach for other classes, for example
cardio-vascular and HIV drugs have very little in common. Therefore, this industry is
a good experiment to address the issues of the effect of diversification and the impact
of financial constraints on the firm’s investment decisions. As mentioned in Chap-
ter 2, the fact that we can observe investment decisions at the project level makes
the pharmaceutical industry a very fruitful ground to test various issues related to
decisions the firm makes.
The goal of this chapter is to use the pharmaceutical industry in order to con-
tribute to this debate. This chapter uses the same data as in Chapter 2. I study
a detailed, project-level sample of 4057 drug candidates that were sponsored by 40
of the largest pharmaceutical firms during the period 1984-2001. Of these projects,
447 were conducted through a contractual alliance with another, smaller company
that had discovered the drug candidate. The remaining 3610 projects are projects
fully owned and developed by the firm, albeit they belong to 12 different disease
classes. This structure of the data allows to investigate the investment decision the
firm makes across different and unrelated diseases classes and comparing decisions
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with respect to fully integrated and non-intergraded (contractual) projects. All these
projects belong to the same internal capital market, and if fully efficient (a` la Stein
(1997)) should all be ranked in order to ”winner pick” the best projects to invest the
limited resources of the firm in.
First, I investigate how the continuation decision depends on the firm’s financial
resources. As the model developed in Section 2.2 predicts, internal projects should
be more sensitive than alliance projects to the constraints the firm faces. I find
that the continuation decision with respect to integrated projects depends on the
amount of cash available to the firm, the existence of other advanced projects in
the firm, and, to a lesser extent, the existence of similar projects in the firm. Non-
integrated projects are less sensitive than integrated projects to the firm’s financial
resources and to the existence of other advanced projects in which the firm could
invest. However, they are sensitive to other similar projects in the firm. This indicates
that large biopharmaceutical firms seem to rank their internal projects relative to each
other across therapeutic classes, and that they assess investment decisions taking into
account their existing constraints. When assessing external projects, the firms seem
to follow a more rigid method, which is much less affected by changes in their financial
resources and other investment opportunities.
Second, I investigate how the degree of diversification of the firm affects its invest-
ment decisions. I find that when a firm has many projects in one therapeutic area, it
will not only affect its decisions regarding continuations of projects in the same area
but also in other areas. A firm will be more likely to continue a projects in an area it
is week in than in an area it is strong in. This result may indicate cross-subsidizing
similar to Berger and Ofek (1995). However, this result can also be due to the fact
that firms do not want to develop products that would cannibalize existing products
and thus reduce their R&D investment when it reaches a certain level in one area.
Finally, I investigate the impact of having a drug approved on the firm’s decisions.
Once a drug is approved the firm receives a high stream of revenues. However this
is not a windfall of cash a` la Blanchard, Lopez-de-Silanes, and Shleifer (1994), but
an expected stream as part of the firm’s business model. Nonetheless, this event has
108
an impact on the firm. The firm needs to invest a lot in Phase IV clinical trial and
marketing and having other projects in the same area might create cannibalization.
I investigate how this event impacts the firm. I find that it reduces the propensity to
continue projects both in the same area but also in other areas. Similar to Lamont
(1997) one division affects the others, in this case, in R&D investments.
The remainder of the chapter proceeds as follows: Section 3.2 outlines the con-
struction of the database and Section 3.3 presents the results. Section 3.4 concludes.
3.2 Data
The main data used in this study is obtained from PJB Publications’ PharmaProjects.
The PharmaProjects is a UK based commercial database that tracks drug compounds
through their stages of development, from as early as pre-clinical laboratory studies to
FDA approval. This database is typically licensed by major pharmaceutical, biotech,
accounting, and law firms for the purpose of learning what the competition is doing.
Since clinical trials are performed by medical institutions that publish the results of
their research, the PharmaProjects is able to gather information on projects of both
public and private companies. In addition to identifying the drug and its sponsoring
organization, the PharmaProjects also gives information on the timeline of devel-
opment (including the dates of Phase I, Phase II, Phase III, and FDA approval or
discontinuation of the project). This database also provides detailed information on
the drug candidates, including the indication it is aimed to cure, its pharmacological
routes, its potential market value and of course the sponsoring firm. This data not
only allows tracking of drug candidates over time, it also allows building a time series
of each firm’s R&D portfolio and its pipeline of drugs.
Data on the alliances is obtained from the databases of Recombinant Capital
(ReCap), a San Francisco-based consulting firm specializing in tracking the biophar-
maceutical industry, and mostly the alliances between the companies in this industry.
As mentioned earlier, one advantage of studying biopharmaceutical firms is the de-
gree of disclosure in this industry. Publicly traded biopharmaceutical firms, like other
concerns, are required by the US Securities and Exchange Commission (SEC) to file
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material documents. Biopharmaceutical companies tend to interpret this requirement
conservatively, and often file alliance contracts. This allows ReCap to gather infor-
mation about alliance contracts between various biopharmaceutical companies even
if one of them is a private company.
The empirical design of this study requires concentrating on firms that have both
internally and externally developed projects. For this purpose, I concentrate on the
40 largest public biopharmaceutical firms. I focus only on public firms for two main
reasons. The quality of information should be equivalent since they have to follow
the same disclosure rules. It also allows me to link the drug development data to
financial information from COMPUSTAT.
I extract from PharmaProjects all the drug development projects data that in-
volves any of those 40 firms and that have valid information. This results in 3610
projects initiated by 40 companies between the years 1984-2001. I do not gather
information on projects initiated after the year 2001 so as to have enough time to get
information on movement to phase II.
I also extract from ReCap information on projects where there was an alliance that
involved one of these 40 companies as the financing side of the alliance. I manually
match these alliances with projects in PharmaProjects using the drug name, the
originator’s name and the start-up’s name. In this study I concentrated on alliances
signed before phase I. In particular, I eliminate alliances where:
• One of the parties is a university, medical center, non-profit organization, or
government agency.
• One of the parties has a controlling interest in the other, either through a
majority equity stake or through a purchase option (e.g., an alliance between a
firm and one of its R&D limited partnerships).
• More than two firms are involved, making the analysis less clean and tractable.
• The agreement as filed contains no information on the stage it which it was
signed.
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• The alliance was signed after phase I had been initiated. The later the stage,
the less the alliance is about research and development, and the more it is about
combining marketing or manufacturing capabilities.
This results in 447 drug candidates. I will refer to projects originated by a firm as
internal and those that were originated by another company and the firm signed an
alliance on as an external project. All this results in 4057 drug development projects,
of which 3610 were internally developed and 447 were externally developed.
Table 3.1 presents summary data (deflated to the year 2000 US Dollar terms)
on the public companies sponsoring the trials in the sample. On average, the public
companies are very large, with mean revenues of over $9 billion, mean assets of almost
$13 billion, mean cash of close to $2.2 billion and mean R&D of about $1 billion. The
average market capitalization is over $32 billion and the mean Q is 3.45. Nonetheless,
there is wide heterogeneity among the firms in the sample. This is mainly due to the
long time series, whereas most of the companies have grown over time to the large
size as indicated by the means. Some of the largest companies in the sample, are
the largest world drug manufacturers. With sales of more that $35 billion, R&D
expenditure of almost $3 billion and more than 100 thousand employees worldwide.
3.2.1 Summary Statistics
A one can see in Table 3.1, the sample of companies is of very large firms. In year 2000
Dollar terms they average sales of almost 10 Billion Dollars, and have assets averaging
more than 12 Billion Dollars. These firms have very large cash reserves, their mean
cash holdings are more than two billion Dollars with a maximum of 13 billion and a
minimum of 277 million. These are clearly not firms in financial distress. Moreover,
these firms have average sales close to 10 Billion Dollars, and a market capitalization
of more than 32 Billion Dollars. This shows that these firms can easily raise additional
funds if they want to.
However, not being financially constrained, and being capable of raising additional
funds does not imply that these firms have unlimited resources. These firms have
very large long term commitments and have long term plans with respect to drug
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development. Moreover, they cannot dilute their concentration on too many different
projects, both from a managerial point of view and from a labor constraint point
of view. Thus, these firm, with all their resources, still need to make decisions of
prioritizing their projects. The long term nature of drug development projects, and
the high cost associated with them, makes these decisions even more complicated and
therefore make it a very instrumenting setup to investigate.
Table 3.2 reports the distribution of projects inside the internal capital markets of
the firms in the sample. As one can see, there are no substantial differences between
the situation in which a firm initiates a new internal projects or a new external
alliance. The average number of projects the firm is undertaking at the time of
initiation is very similar. Though one has to notice that although the means are
similar the distribution and somewhat different. When looking at the other number
of projects in Phase I, the main difference is clear. A firm will not start an alliance
when it has no other projects in Phase I in the same therapeutical class, or conversely
when it has many projects in the same class. The former is probably due to the fact
that the small firm will be reluctant to sign a contract with a firm that cannot add
value as it has no experience in the field. The latter is probably due to the fact that a
large firm has very little to gain from an alliance when it is already trying to manage
many internal projects which probably cover most avenues of R&D available.
These figures clearly indicate that the large firms try to manage their R&D pipeline
by deciding on beginning and ending of new projects and probably on discontinuation
and continuation of existing projects. The purpose of this chapter is to analyze those
decisions.
3.3 Empirical Analysis
3.3.1 Allocation of Resources
Section 2.5.1 presents evidence that pharmaceutical firms are more prone to dis-
continue integrated projects than non-integrated projects when deciding whether to
advance from Phase I to Phase II. It also presents evidence that those projects are of
lower quality, both defined by the probability of advancing to Phase II and getting
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FDA approval. The model in Section 2.2 suggests that the reason that firms would
promote further non-integrated projects that would yield lower quality projects is the
rigidity of the contract governing them. Therefore, as Prediction 3 suggests, changes
in the firm’s financial condition should have a larger effect on internal projects than
on external projects.
In order to test this prediction, I use several measures for factors that can affect
the decision of a firm whether to continue an R&D project. First, I use the amount
of cash (as measured by COMPUSTAT, in US Dollars deflated to the year 2000) the
company has at the end of the year it started undertaking Phase I of the project. I
normalize the amount of cash by the number of projects at that time in the firm. The
results are very robust to different measures on normalization such as a weighted sum
of projects, weighted by the expected cost of each project. Second, I use the number
of other projects the firm has at the moment of decision. I normalize the number
of projects by sales (in US Dollars deflated to the year 2000) of the firm that year
so that they will proxy for the opportunity of the firm and not to its size. Again,
the results using this variable are robust to using other deflators. All the regressions
using the number of projects are robust to using only internal or internal and external
projects. Third, I use not only the number of projects in the firm in general but also
the number of projects in the firm targeting the same therapeutic class as the project
I am looking at. This number is normalized in the same way as is the number of
projects in the firm.
Table 3.3 presents the results of the regression of the probability of advancing
from Phase I to Phase II on cash and the number of projects in the pipeline of the
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firm, using the same controls used in section 2.5.1.
Pr[Advancing from Phase I to Phase II ] =
= α + β1Alliance+ β2Novelty + β3Bio+ β4LGMKT + β5SMMKT+
+ γ1 Cash+ γ2 Cash · 1Alliance+
+ γ3 All Projects+ γ4 All Projects · 1Alliance+
+ γ5 Same Therapy Projects+ γ6 Same Therapy Projects · 1Alliance+
+
∑
i∈Company
1i +
∑
j∈Therapy
1j +
∑
k∈Y ear
1k + ² (3.1)
The proxy for the firm’s financial constraint, the amount of cash the company has,
affects the decision regarding internal projects but not external projects. The effect,
though statistically significant, does not have a large economic significance. This is
probably due to the fact that if they want, those large biopharmaceutical companies
can raise added cash. These firms are sensitive in their decision to the cash at hand,
indicating that they do not promote projects unless they have the resources to do so,
and since they do not have endless resources they probably promote those projects
that have the higher probability of success. When adding to the regression the overall
number of projects in the firm we get a similar picture. The decision whether to
advance from Phase I to Phase II is negatively related to the product pipeline. If
the firm has many other projects (scaled by sales) it will be less likely to advance a
specific project to the next phase. This result coupled with the cash result seems to
indicate a behavior similar to ”winner picking” by the firm. Projects are more likely
to advance if there is more cash, less projects overall in the pipeline and if that specific
project is more novel or targets a larger potential market. Non-integrated projects,
on the other hand, don’t seem to exhibit the same behavior. They don’t seem to
be very sensitive to either the amount of cash in the firm or the firm’s pipeline. As
prediction 3 suggests, this can be explained by the fact that non-integrated projects
are governed by a pre set contract. If the projects meet their goals, it is very difficult
to renegotiate (or break) the contract simply because the firm’s opportunity set has
changed. This rigidity seems to be at the heart of the above results. It must be noted
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that both integrated and non-integrated projects show sensitivity to the existence of
a pipeline of projects in the same therapeutic class. This is not explicitly predicted by
the model. This could be explained by the fact that if the firm has a similar project
at the same stage it is easier for it to terminate an external project. This could be
due to the fact that this public knowledge of such projects reduces the asymmetric
information that is involved in the signal perceived by the termination of an alliance.
In such a case, the market or other firms will know that the reason for termination of
the contract is not bad results but a clear change in the firm’s priority, mitigating any
reputation problem that may arise generally from the discontinuation of an alliance.
3.3.2 Diversification
Table 3.4 reports the results of the impact of diversification on the firm’s investment
decisions. Concentration is the ratio of projects in a specific therapeutic class to the
total number of projects the firm is undertaking. This variable is a proxy for how
diversified the firm is. Similar to Lamont (1997), I am trying to asses what is the
level of diversification of the different ”segments” of the firm. In this case, I use the
different therapeutic classes in order to get some sense how one segment of the firm
is important compared to the other activities of the firm.
Table 3.4 Panel A, reports summary statistics for the concentration variable.
There is no statistically significant difference between the level of concentration of
a therapeutic class between the classes in which an internal project is initiated or an
alliance project is contracted. As mentioned in section 3.2.1, the main difference in
intimation is the standard deviation, i.e. firm will be less likely to initiate a project
when they have no projects or too many in a specific therapeutic class.
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Table 3.4 Panel B, reports the results of the estimation of the following regression:
Pr[Advancing from Phase I to Phase II ] =
= α + β1Alliance+ β2Novelty + β3Bio+ β4LGMKT + β5SMMKT+
+ γ1 Concentration+ γ2 Concentration · 1Alliance+
+
∑
i∈Company
1i +
∑
j∈Therapy
1j +
∑
k∈Y ear
1k + ² (3.2)
The more concentrated a therapeutic class the less likely a firm to advance each and
every project in that therapeutic class forward from Phase I to Phase II. Contrary to
Table 3.3 where one possible explanation to the result is that the higher selectivity of
the firm could be due simply to the higher number of drugs in that specific class, in
this case a high level of concentration does not imply directly that that specific class
has many alternative projects or that other classes do not have enough of those.
The more concentrated a therapeutic class, a firm is 8% less likely to advance a
project from Phase I to Phase II. This pattern of behavior is not different whether
a project is undertaken as fully owned by the firm, or if it is governed by contract.
Beyond the fact that internal and alliance projects are treated by the firm in a way
that is not different, it is quite interesting to note the behavior of the firm due to the
firm’s level of diversification. The less diversified the firm is, the less likely it is to
continue a project in the division in which it is strong. This is indeed, an indication
that the investment decision in one division has an effect on the other division. Strong
divisions are less likely to have a project advance than weak divisions. From the firm’s
point of view this could be due to the need to diversify the firm’s portfolio, or in order
not to risk the likelihood of having one project cannibalize the other.
Next, in order to try and understand deeper what could be driving these results,
I try to proxy the opportunity set of the firm.
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3.3.3 Diversification and Opportunity
Table 3.5 reports the results of the following regression:
Pr[Advancing from Phase I to Phase II ] =
= α + β1Alliance+ β2Novelty + β3Bio+ β4LGMKT + β5SMMKT+
+ γ1 Concentration+ γ2 Concentration · 1Alliance+
+ γ3 Average Trial + γ4 Average Trial · 1Alliance+
+
∑
i∈Company
1i +
∑
j∈Therapy
1j +
∑
k∈Y ear
1k + ² (3.3)
Where Concentration receives the value of the ratio of projects in a specific thera-
peutic class to the total number of projects the firm is undertaking. And Average
Trial is the average level of clinical trials (I, II, III) in that therapeutic class, this is
an instrument for the opportunity the firm faces. Average Trial is used to proxy the
opportunity set the firm faces.
The basic result highlighted in Section 3.3.2 is not altered, thought its statistical
significance is reduced. The intriguing result is the fact that the average trial, proxying
for the other opportunities the firm has in that same therapeutic class, has quite a
large impact on the firm. The more advanced the trials, the less likely is the firm
to take a project forward. Again, in this matter there is no statistically significant
difference between the way a firm treats its projects that are governed by ownership
and its projects that are governed by contract. However, the main result of this table
is that when a firm has many projects in one therapeutic area, it will not only affect
its decisions regarding continuations of projects in the same area but also in other
areas. A firm will be more likely to continue a projects in an area it is week in than
in an area it is strong in. This result may indicate cross-subsidizing similar to Berger
and Ofek (1995). However, this result can also be due to the fact that firms do not
want to develop products that would cannibalize existing products and thus reduce
their R&D investment when it reaches a certain level in one area.
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3.3.4 Approval
Table 3.6 reports the results of the following regression:
Pr[Advancing from Phase I to Phase II ] =
= α + β1Alliance+ β2Novelty + β3Bio+ β4LGMKT + β5SMMKT+
+ γ1 Approved − Same Class+ γ2 Approved − Same Class · 1Alliance+
+ γ3 Approved − Other Classes+ γ4 Approved − Other Classes · 1Alliance+
+
∑
i∈Company
1i +
∑
j∈Therapy
1j +
∑
k∈Y ear
1k + ² (3.4)
Where Approved - Same Class, is a dummy variable that receives the value of 1 if the
firm had a drug approved in the previous 12 month in the same therapeutic class, and
0 otherwise. Approved - Other Classes, is a dummy variable that receives the value
of 1 if the firm had a drug approved in the previous 12 month in other therapeutic
classes, and 0 otherwise. These variables, give a sense of the the effect success in one
division (accompanied by its future cash flows) has on the same division and others.
Table 3.6, Columns 1 an 2, give the impact a project has on the same division. For
an internal project, having a drug approved will reduce the likelihood of the firm to
continue a project and advance it from Phase I to Phase II. However, for an alliance
project the difference (though still negative) is much smaller. Again, the existence of
a contract reduces the willingness or capability of the firm to discontinue a project,
even if an identical internal project, would have been treated differently.
This result shows that decisions on R&D projects are affected by new approved
drugs. There are two potential reasons for ut. First, once a drug is approved there are
large costs for the Phase IV, marketing, and other necessary expenditures. Second,
there is always a fear of cannibalization. As a drug receives a patent protection of at
least seven years, it allows the firm to invest in other venture. In order to look into
it, I add the effect to the other divisions in the firm.
Table 3.6, Columns 3 an 4, give the impact a project has on the other divisions.
For an internal project, having a drug approved in an other division, will increase
the propensity to take a project forward. This effect is similar for projects that are
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governed by ownership and projects that are governed by contract. When a firm has a
future cash flow due to an approved drug, thus, it reduces its investment in potentially
similar projects, and concentrates its funds in other un-related investments.
3.4 Conclusion
In this chapter, I investigate how the continuation decision depends on the firm’s
financial resources. As the model developed in Section 2.2 predicts, internal projects
should be more sensitive than alliance projects to the constraints the firm faces. I
find that the continuation decision with respect to integrated projects depends on
the amount of cash available to the firm, the existence of other advanced projects in
the firm, and, to a lesser extent, the existence of similar projects in the firm. Non-
integrated projects are less sensitive than integrated projects to the firm’s financial
resources and to the existence of other advanced projects in which the firm could
invest. However, they are sensitive to other similar projects in the firm. This indicates
that large biopharmaceutical firms seem to rank their internal projects relative to each
other across therapeutic classes, and that they assess investment decisions taking into
account their existing constraints. When assessing external projects, the firms seem
to follow a more rigid method, which is much less affected by changes in their financial
resources and other investment opportunities.
Second, I investigate how the degree of diversification of the firm affects its invest-
ment decisions. I find that when a firm has many projects in one therapeutic area, it
will not only affect its decisions regarding continuations of projects in the same area
but also in other areas. A firm will be more likely to continue a projects in an area it
is week in than in an area it is strong in. This result may indicate cross-subsidizing
similar to Berger and Ofek (1995). However, this result can also be due to the fact
that firms do not want to develop products that would cannibalize existing products
and thus reduce their R&D investment when it reaches a certain level in one area.
Finally, I investigate the impact of having a drug approved on the firm’s decisions.
Once a drug is approved the firm receives a high stream of revenues. However this
is not a windfall of cash a` la Blanchard, Lopez-de-Silanes, and Shleifer (1994), but
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an expected stream as part of the firm’s business model. Nonetheless, this event has
an impact on the firm. The firm needs to invest a lot in Phase IV clinical trial and
marketing and having other projects in the same area might create cannibalization.
I investigate how this event impacts the firm. I find that it reduces the propensity to
continue projects both in the same area but also in other areas. Similar to Lamont
(1997) one division affects the others, in this case, in R&D investments.
Future research will concentrate in better understanding whether this is the case
of a weak division being subsidized by a strong division, or a sound firm product
development strategy.
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3.5 Tables - Chapter 3
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Table 3.1: Summary Statistics on Sample Companies
This table reports summary statistics on the firms in the sample. The numbers are averages
of all the firm-year observations. Sales, assets, cash, market cap are in Millions of Dollars.
Number of employees is in thousands. Q is defined as the market value of equity the book
value of assets less the book value of equity divided by the book value of assets. All the
numbers are deflated to year 2000 Dollars.
Statistic Sales Assets Cash R&D Market Cap Q Employees
Mean 9,751.33 12,663.86 2,158.25 1,034.74 32,684.01 3.45 38.84
Median 8,030.59 10,952.53 1,314.33 934.27 27,952.96 3.51 42.22
Std 9,691.63 12,219.54 3,053.65 844.02 28,937.93 1.09 35.76
Max 35,198.89 42,362.05 12,629.75 2,945.42 106,737.00 6.71 136.61
Min 14.08 277.71 179.91 40.70 606.57 1.52 0.17
25% 1,029.82 2,318.71 485.73 279.91 5,918.06 2.74 4.25
75% 15,350.96 18,720.97 2,489.55 1,716.58 55,619.64 4.03 52.16
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Table 3.2: Summary Statistics - Other Projects in the Internal Job Market
This table
All Internal Alliance
All Projects
Number of Other Phase 3 projects - Mean 9.09 8.97 10.12
Number of Other Phase 3 projects - Median 8 8 7
Number of Other Phase 3 projects - STD 7.91 7.66 9.78
Number of Other Phase 2 projects - Mean 14.03 13.63 17.52
Number of Other Phase 2 projects - Median 10 10 13
Number of Other Phase 2 projects - STD 12.70 12.30 15.38
Number of Other Phase 1 projects - Mean 23.49 24.66 13.28
Number of Other Phase 1 projects - Median 0 0 10
Number of Other Phase 1 projects - STD 74.09 78.05 11.99
Same Therapeutic Class
Number of Other Phase 3 projects - Mean 1.21 1.21 1.25
Number of Other Phase 3 projects - Median 0 1 0
Number of Other Phase 3 projects - STD 1.93 1.92 1.98
Number of Other Phase 2 projects - Mean 1.82 1.78 2.13
Number of Other Phase 2 projects - Median 1 1 1
Number of Other Phase 2 projects - STD 2.47 2.45 2.59
Number of Other Phase 1 projects - Mean 2.84 2.98 1.70
Number of Other Phase 1 projects - Median 0 0 1
Number of Other Phase 1 projects - STD 10.25 10.79 2.23
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Table 3.3: Regression of the Probability of Advancing from Phase I to Phase II -
Resource Allocation Across Different Projects
The model estimated is a linear probability regression. The dependent variable is the probability of advancing from
phase I to phase II in the 2 years following phase I. It takes the value of 1 if the drug advanced to phase II and 0
if not. An alliance project is defined as a project that was originated by another company and an alliance contract
was signed. 1) Cash is the amount of cash (deflated to year 2000 Dollar terms) the company has scaled by the total
number of projects the company had 3 years earlier. 2) All Projects - is the total number of projects in the firm
scaled by the firm’s sales (deflated to year 2000 Dollar terms). 3) Same Therapy Projects - is the total number of
projects in the firm targeting the same therapeutic class scaled by the firm’s sales (deflated to year 2000 Dollar
terms). The same controls are used as described in Table 2.5. The t-statistics, reported in parentheses, are based on
robust standard errors that are corrected for firm-level clustering.
(1) (2) (3) (4) (5)
Alliance 0.0860 0.1081 0.1191 0.1635 0.1771
(2.61)** (2.32)** (2.71)** (3.18)*** (3.10)***
Cash 0.0012 0.0019 0.0019 0.0013 0.0023
(8.02)*** (6.24)*** (6.21)*** (4.45)*** (6.08)***
Cash*Alliance -0.0010 -0.0016 -0.0015 -0.0010 -0.0020
(7.15)*** (6.01)*** (5.88)*** (4.10)*** (5.77)***
All Projects -0.0039 -0.0030 -0.0070 -0.0089
(1.95)** (1.98)** (2.92)*** (2.96)***
All Projects*Alliance 0.0028 0.0034 0.0068 0.0081
(1.90)** (1.95)** (2.81)*** (2.72)***
Same Therapy -0.0192 -0.0190 -0.0137 -0.0134
Projects (1.84)* (1.80)* (2.01)** (2.05)**
Same Therapy -0.0015 -0.0017 -0.0074 -0.0094
Projects*Alliance (1.99)** (1.97)** (2.52)*** (2.85)***
Novelty 0.0132 0.0121 0.0110 0.0106 0.0376
(1.90)* (1.97)** (2.12)** (2.23)** (2.65)**
Bio 0.0635 0.0743 0.0760 0.0734 0.0980
(1.95)* (2.17)** (2.32)** (2.41)** (2.60)**
Market Size - Large 0.0669 0.0139 0.0036 0.0954 0.1250
(1.01) (1.17) (1.04) (2.11)** (2.03)**
Market Size - Small -0.0275 -0.0360 -0.0316 -0.0361 -0.0241
(1.76)* (1.39) (1.15) (1.26) (0.81)
Observations 2985 2985 2985 2985 2985
R2 0.13 0.14 0.15 0.16 0.27
Company FE No No Yes Yes Yes
Therapeutic Class FE No No No Yes Yes
Year FE No No No No Yes
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Table 3.4: Regression of the Probability of Advancing from Phase I to Phase II -
Diversification
The model estimated is a linear probability regression. The dependent variable is the probability
of advancing from phase I to phase II in the 2 years following phase I. It takes the value of 1 if
the drug advanced to phase II and 0 if not. There are several controls as described in Table 2.5.
Concentration is the ratio of projects in a specific therapeutic class to the total number of projects
the firm is undertaking. Panel A reports summary statistics for the concentration variable. Panel
B reports the regression. The t-statistics, reported in parentheses, are based on robust standard
errors that are corrected for firm-level clustering.
Panel A: Summary Statistics
Mean Median StD
Internal 0.1264 0.9097 0.6310
Alliance 0.1241 0.1111 0.2431
Panel B: Regression
(1) (2) (3) (4) (5)
Alliance 0.1591 0.197 0.2074 0.2145 0.2381
(7.71)*** (5.02)*** (4.68)*** (5.44)*** (5.30)***
Novelty 0.0272 0.0289 0.0208 0.0322
(2.45)** (2.55)** (2.29)** (2.41)**
Bio 0.0817 0.0772 0.0761 0.0722
(2.51)** (2.37)** (2.41)** (2.35)**
Market Size - Large 0.0397 0.1535 0.0377 0.1521
(0.30) (2.42)** (1.86)* (2.32)**
Market Size - Small -0.0532 -0.0279 -0.0485 -0.0224
(2.20)** (1.32) (2.08)** (1.89)*
Concentration -0.0875 -0.0675
(3.21)*** (3.32)***
Concentration*Alliance -0.0021 -0.0038
(0.43) (0.51)
Observations 2985 2985 2985 2985 2985
R2 0.10 0.11 0.25 0.12 0.25
Company FE No No Yes No Yes
Therapeutic Class FE No No Yes No Yes
Year FE No No Yes No Yes
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Table 3.5: Regression of the Probability of Advancing from Phase I to Phase II -
Diversification and Opportunity
The model estimated is a linear probability regression. The dependent variable is the probability of
advancing from phase I to phase II in the 2 years following phase I. It takes the value of 1 if the drug
advanced to phase II and 0 if not. There are several controls as described in Table 2.5. Concentration
receives the value of the ration of projects in a specific therapeutic class to the total number of
projects the firm is undertaking. Average Trial is the average level of clinical trials (I, II, III) in
that therapeutic class, this is an instrument for the opportunity the firm faces. The t-statistics, re-
ported in parentheses, are based on robust standard errors that are corrected for firm-level clustering.
(1) (2) (3) (4)
Alliance 0.2145 0.2381 0.2216 0.2415
(5.44)*** (5.30)*** (5.45)*** (5.33)***
Novelty 0.0208 0.0322 0.0208 0.0301
(2.29)** (2.41)** (2.27)** (2.43)**
Bio 0.0761 0.0722 0.0770 0.0691
(2.41)** (2.35)** (2.50)** (2.38)**
Market Size - Large 0.0377 0.1521 0.0346 0.1502
(1.86)* (2.32)** (1.88)* (2.35)**
Market Size - Small -0.0485 -0.0224 -0.0491 -0.0224
(2.08)** (1.89)* (2.06)** (1.87)*
Concentration -0.0875 -0.0675 -0.0721 -0.0325
(3.21)*** (3.32)*** (2.05)** (1.76)*
Concentration*Alliance -0.0021 -0.0038 -0.0035 -0.0041
(0.43) (0.51) (0.52) (0.55)
Average Trial -0.0943 -0.0721
(3.76)*** (3.42)***
Average Trial*Alliance -0.0072 -0.0043
(0.89) (0.76)
Observations 2985 2985 2985 2985
R2 0.12 0.25 0.14 0.26
Company FE No Yes No Yes
Therapeutic Class FE No Yes No Yes
Year FE No Yes No Yes
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Table 3.6: Regression of the Probability of Advancing from Phase I to Phase II -
Approval
The model estimated is a linear probability regression. The dependent variable is the probability
of advancing from phase I to phase II in the 2 years following phase I. It takes the value of 1 if the
drug advanced to phase II and 0 if not. The controls and Fixed Effects are the same as described in
Table 3.3. Approved is a dummy variable that receives the value of 1 if the firm had a drug approved
in the previous 12 month and 0 otherwise.
(1) (2) (3) (4)
Alliance 0.2103 0.2234 0.2154 0.2454
(5.55)*** (5.35)*** (5.48)*** (5.43)***
Novelty 0.0277 0.0366 0.0264 0.0311
(2.27)** (2.45)** (2.29)** (2.51)**
Bio 0.0689 0.0711 0.0793 0.0701
(2.41)** (2.34)** (2.52)** (2.35)**
Market Size - Large 0.0377 0.1521 0.0346 0.1502
(1.86)* (2.32)** (1.88)* (2.35)**
Market Size - Small -0.0485 -0.0224 -0.0491 -0.0224
(2.08)** (1.89)* (2.06)** (1.87)*
Approved - Same Class -0.1089 -0.0972 -0.1103 -0.1001
(3.36)*** (3.51)*** (3.38)*** (3.53)***
Approved-Same*Alliance 0.0681 0.5120 0.0701 0.0489
(3.01)*** (3.12)*** (3.09)*** (3.21)***
Approved - Other Class 0.0641 0.0713
(3.64)*** (3.48)***
Approved-Other*Alliance 0.0210 0.2650
(0.58) (0.86)
Observations 2985 2985 2985 2985
R2 0.12 0.25 0.14 0.26
Company FE No Yes No Yes
Therapeutic Class FE No Yes No Yes
Year FE No Yes No Yes
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